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ABSTRACT 
Progressive familial heart block type II (PFHBII) is an inherited cardiac conduction disorder of 
unknown aetiology, which has been described in a South African family. The disorder was 
mapped to a 2.9 centimorgan (cM) locus on chromosome 1q32.2-32.3. Clinically, PFHBII 
manifests cardiac conduction aberrations, that progress to a disease of the heart muscle, dilated 
cardiomyopathy (DCM). DCM is also reported as an end phase in hypertrophic cardiomyopathy 
(HCM), another heart muscle disorder. These cardiomyopathies are genetically heterogeneous 
with some of the genes reported as causes of both disorders. Therefore, genes identified as causes 
of HCM and DCM were considered plausible candidates for PFHBII mutation analysis. 
Additionally, this study provided an opportunity to assess potential modifiers of HCM. HCM 
exhibits marked phenotypic variability, observed within and between families harbouring the 
same causative mutation.  
 
Genes within the PFHBII locus were selected for PCR-SSCP analysis based on homology to 
genes previously reported as causing conduction system disorders associated with arrhythmias, 
DCM and/or HCM. Results were confirmed by direct sequencing and association between the 
detected variants and HCM parameters was assessed using a quantitative transmission 
disequilibrium test (QTDT).  
 
Eleven plausible candidate genes were selected within the PFHBII locus and two of the genes, 
PFKFB2 and ATF3, that encode for 6-phosphofructo-2,6-bisphosphatase (PFK-2/FBPase-2) and 
activating transcription factor 3 (ATF3), respectively, were analysed for PFHBII-causing and 
HCM main locus and/or HCM modifying mutations. Mutation analysis of PFKFB2 and ATF3 in 
the PFHBII family revealed no PFHBII causal mutation. PFKFB2 and ATF3 were later localised 
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outside the PFHBII locus, and, therefore, were excluded as PFHBII plausible candidates. Further 
analysis of the two genes for HCM main locus and/or HCM modifying mutations in the HCM 
panel identified several sequence variants. QTDT analysis of these variants showed no significant 
association. 
 
Completion of the Human Genome Project (HGP) and annotation of new genes within the 
PFHBII locus allowed the identification of more PFHBII plausible candidate genes. Identification 
of causal mutations in plausible PFHBII candidate genes will allow molecular diagnosis of 
PFHBII pathophysiology. Furthermore, identification of both HCM-modifying and HCM-causing 
genes will give insight into the phenotypic variability noted among South African HCM-affected 
individuals and into the molecular cause of the disease among individuals with HCM-like clinical 
features. 
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OPSOMMING 
Progressiewe familiële hartblok tipe II (PFHBII) is ŉ oorgeërfde hart geleidingsiekte van 
onbekende etiologie wat in ŉ Suid-Afrikaanse familie beskryf is. Die siekte is ŉ 2.9 sentimorgan 
(cM) lokus op chromosoom 1q32.2-32.3 gekarteer. Klinies presenteer PFHBII met 
geleidingsfwykings wat uitloop op gedilateerde kardiomiopatie (DCM). DCM word ook 
gerapporteer as ŉ endfase in hipertrofiese kardiomiopatie (HCM), ŉ ander hartspiersiekte. Die 
kardiomiopatieë is geneties heterogeen, met ŉ aantal gene wat as oorsaak van altwee 
siektetoestande gerapporteer word. Daarom is alle gene wat geïdentifiseer is as oorsake van DCM 
en HCM, as moontlike kandidaatgene vir PFHBII mutasieanaliese beskou. Bykomend het hierdie 
studie die geleentheid gebied om potensiële modifiseerders van HCM te assesseer. HCM toon 
beduidende fenotipiese variasie binne en tussen families wat dieselfde siekteveroorsakende 
mutasie het. 
 
Gene binne die PFHBII-lokus is geselekteer vir PCR-SSCP-analiese gebaseer op homologie met 
gene wat voorheen gerapporteer is om betrokke te wees by geleidingsiesisteemsiektes, 
geassosieerde arritmieë, DCM en/of HCM. Resultate is bevestig deur volgordebepaling. 
Assosiasie tusssen ontdekte variante en die siekteparameter is bepaal met ŉ kwantitatiewe 
transmissie disekwilibrium toets (QTDT). 
 
Elf moontlike kandidaatgene in die PFHBII-lokus is geselekteer en twee van die gene, PFKFB2 
en ATF3, wat kodeer vir 6-fosfofrukto-2,6-bifosfatase (PFK-2/FBPase-2) en 
aktiveringstranskripsiefaktor 3 (ATF3) respektiewelik, is vir PFHBII-oorsakende en HCM-
hooflokus en/of HCM-modifiseerende mutasies ondersoek. Mutasie-analiese van PFKFB2 en 
ATF3 in die PFHBII-familie het nie ŉ siekteveroorsakende mutasie onthul/uitgelig nie. PFKFB2 
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en ATF3 is later buite die PFHBII-lokus geplaas en dus ook as moontlike PFHBII-kandidate 
uitgesluit. Verdere ondersoek van díe twee gene vir HCM-hooflokus en/of HCM-modifiserende 
mutasies in die HCM-paneel het ŉ aantal volgorde variante geïdentifiseer. QTDT-analiese van 
die variante het geen beduidende assosiasies aangetoon nie. 
 
Voltooiing van die Menslike Genoom Projek (HGP) en annotasie van nuwe gene in die PFHBII-
lokus het tot die identifikasie van verdere moontlike PFHBII-kandidaatgene gelei. Identifikase 
van siekte-veroorsaakende mutasies in die moontlike PFHBII-kandidaatgene sal die molekulêre 
diagnose van PFHBII toelaat en insig in die patofisiologie van die siekte gee. Verder, 
identifikasie van beide HCM-veroorsakende of HCM-modifiserende gene kan insig gee in die 
fenotipiese varieerbaarheid wat onder Suid-Afrikaanse HCM-geaffekteerde individue 
waargeneem word en ook in die molekulêre oorsake van die siekte in individue met HCM-
soortige kliniese kenmerke. 
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CHAPTER 1 
 
STUDY OUTLINE 
The present study has two main facets, the first was the search for progressive familial heart 
block-type II (PFHBII)-plausible candidate genes within a locus encompassed by markers 
D1S70 and D1S505, on chromosome 1q32.2-q32.3, to which PFHBII was mapped by P. 
Fernandez in a previous study (personal communication). PFHBII is a cardiac conduction 
system disorder that can progress to the cardiac muscle disorder, dilated cardiomyopathy 
(DCM). Although the genetic cause of PFHBII has not been identified, DCM, which is one of 
the PFHBII clinical features, is a cardiac muscle disorder that has been widely studied, with 
several genes implicated as causing the disease.  
 
DCM is not only genetically heterogeneous, but clinical variability has also been noted with 
some affected individuals also presenting with cardiac conduction system defects (Fatkin et 
al., 1999; Arbustini et al., 2002; Itoh-Satoh et al., 2002). The conduction system defect has 
been noted in DCM-affected individuals who harbour lamin A/C (Fatkin et al., 1999; 
Arbustini et al., 2002) and titin (Itoh-Satoh et al., 2002) mutations. Based on the premise that 
DCM is one of the clinical features of PFHBII, genes encoding proteins that are structurally 
and functionally related to previously identified DCM-causative genes may be relevant for 
PFHBII-causing mutation analysis. Furthermore, DCM-causing mutations have been 
identified in genes in which certain mutations have been shown to cause hypertrophic 
cardiomyopathy (HCM). HCM, like DCM, is a cardiac muscle disorder that is also 
characterised by genetic heterogeneity (Towbin, 2000). Therefore, DCM- and HCM-causative 
genes and genes that cause cardiac conduction disorders associated with arrhythmias were 
used as a reference to search for analogous genes that have homologous functional domains 
and which lie within the PFHBII locus. Bioinformatics tools were used to identify these genes 
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and other candidate genes that encode proteins which are structurally and/or functionally 
important in cardiac tissue, which lie within the PFHBII locus. Prioritised candidate genes 
were then screened for the PFHBII-causative mutation in a panel of individuals from the 
PFHBII family. 
 
The second facet of the study was to investigate if the genes chosen as plausible PFHBII 
candidates played a role in the development of HCM, or were involved in modifying the 
phenotypic expression of the disease. Consequently, the selected genes were also screened for 
HCM main locus mutations and/or HCM modifying variants in a panel of unrelated affected 
individuals. The HCM panel consisted of HCM-affected individuals with known casual 
mutations and individuals with HCM-like phenotype. Therefore, screening new plausible 
candidate genes might elucidate the genetic causes of HCM in those individuals with HCM-
like phenotype and the phenotypic variability among affected individuals with identical causal 
mutations. Plausible PFHBII candidate genes were screened for HCM main locus mutations 
and/or HCM modifying variants based on the fact that DCM-causing mutations have been 
identified in genes in which certain mutations were shown to cause HCM (e.g. DCM-causing 
mutations were also identified in the β-myosin heavy chain-, cardiac troponin T-, cardiac 
actin-, titin- and α-tropomyosin-encoding genes, all of which are HCM-causative genes) 
(Regitz-Zagrosek et al., 2000; Kamisago et al., 2000; Olson et al., 1998; Siu et al., 1999; 
Olson et al., 2001). Furthermore, HCM-affected indiviuals have been reported to develop 
DCM-like phenotypes at a later stage of the disease, although it is still unclear whether this in 
an end-stage HCM phenotype or a transition from HCM to DCM (Seidman and Seidman, 
2001).  
 
The first section of the literature review describes the structure of the heart, focusing mainly 
on the cardiac conduction system and the working cardiac muscle (myocardium). Structural 
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components of the myocardium, the sarcomere and the cytoskeleton, and their protein 
complexes will be discussed as abnormalities in these structures have been implicated as 
causing either DCM or HCM (reviewed by Seidman and Seidman, 2000). Also included in 
the introduction is a background to the Human Genome Project (HGP), which has provided 
data and tools that have facilitated identifying genes implicated as causes of genetically 
inherited diseases (Baxevanis, 2001; Galperin, 2004). The data generated as a result of 
sequencing and annotating the human genome is integrated and stored in various databases. 
This information can be assessed and “mined” through the use of bioinformatics, which is 
also discussed in section 1.2.2. 
 
1.1 The Heart 
This section focuses on the cardiac conduction system and the working cardiac muscle 
(myocardium), which are important components of the heart (Opie, 1991). Each of these 
components will be discussed, focusing on their structures and how they function. 
 
1.1.1 Structure of the cardiac conduction system 
The cardiac conduction system coordinates the production and pathway of the action potential 
that causes heart beats (Ganong, 1991). It consists of specialised cells that control the rate and 
rhythm of the heart beat by controlling the rate and direction of electrical impulses as they are 
propagated through the heart. The adult cardiac conduction system consists of separate 
morphological components (Fig. 1.1): the sinoatrial (SA) node and the atrioventricular (AV) 
node, which perform distinct functions (Davies et al., 1983; Ganong, 1991; Moorman et al., 
1998). The SA node is located in the upper part of the right atrium and is considered to be the 
pacemaker because of the role it plays in initiating conduction of impulses. The AV node is 
located lower in the right atrium and forms the slow-conducting myocardial region. Other 
components include the AV bundle (bundle of His), the right and left bundle branches, and 
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the peripheral Purkinje fibre network, which form the fast-conducting pathway (Davies et al., 
1983; Ganong, 1991; Moorman et al., 1998). 
 
 
Figure 1.1 Schematic representation of a heart. Components of the cardiac conduction system and 
conduction of impulses (shown in yellow) are indicated. The conduction system consists of the 
following: the sinoatrial node (SA), a branch extending from the sinoatrial node to the upper part of 
the left atrium, the atrioventricular node (AV), the bundle of His which branches into the left and right 
bundle branches located each side of the interventricular septum, and small branches called Purkinje 
fibres. Taken from http://www.cotc.edu/vstone/webdocek.html. 
 
 
1.1.2 Propagation of impulses 
The SA node can either receive signals from the rest of the body or automatically self-activate 
to initiate impulse conduction (Wahl, 1999). It receives signals from the body via hormones 
from the blood and via neurons from the sympathetic and parasympathetic nervous system, 
acting in a modulatory function only. Once the impulses are initiated in the SA node, they 
spread quickly through the right atrium via muscle cells in the myocardium (Fig. 1.1). The 
impulses are transmitted through the gap junctions in the intercalated disks where the 
cytoplasm of one cardiac cell (cardiomyocyte) connects to, and is continuous with, the 
cytoplasm of an adjacent cardiomyocyte. Impulses reach the AV node and are delayed for 
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about one tenth of a second, long enough to allow the atrium to contract and add blood to the 
ventricle, before the ventricle gets the signal to contract (Ganong, 1991; Rhoades and 
Pflanzer, 1996).  
 
Impulses travel from the AV node through the bundle of His towards the ventricles. The 
bundle of His divides into thinner branches, the left and right bundle branches and the bundle 
branches divide further into thinner branches called the Purkinje fibres, which transmit 
impulses to all parts of the ventricles. From the Purkinje fibres, the impulses travel from one 
myocardial cell to the adjacent cell of the ventricular muscle layer. The cells in the lower part 
of the ventricle contract slightly earlier than the cells in the upper part and this allows blood to 
be ejected from the ventricles. The process normally takes a fraction of a second, with all cells 
contracting nearly simultaneously, and it can be monitored by an electrocardiogram (ECG) 
(Fig. 1.2), which measures the path of impulses as they travel through the CCS and is 
performed by applying electrodes to the skin. 
 
 
Figure 1.2 A diagram of a typical electrographic recording. The action potential on different regions 
of the cardiac conduction system is represented by different ‘waves’. Taken from 
http://www.cotc.edu/vstone/webdocek.html. 
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1.1.3 Structure of the working myocardium 
This section is focused on the structure of the muscle fibre, highlighting the proteins 
comprising the contractile unit (sarcomere) and its surrounding proteins, which make up the 
cytoskeleton.  
 
The working myocardium consists of muscle fibres (myofibrils) that branch and interdigitate, 
each fibre forming a complete unit surrounded by a cell membrane called the sarcolemma. 
The sarcolemma forms a tubular network which extends to form an extensive network called 
transverse or T-tubules (Fig. 1.3) (Ganong, 1991; Opie, 1991). Cardiac myocytes are 
connected to each other end-to-end by a highly specialised and altered sarcolemma 
(intercalated discs) (Ganong, 1991; Rhoades and Pflanzer, 1996; Opie, 1991). Intercalated 
discs are specialised cell-cell junctions that form regions of low electrical resistance, hence 
providing mechanical and electrical coupling between cells. They are composed of adherens 
junctions (containing N-cadherin, catenins and vinculin), desmosomes (containing desmin, 
desmoplakin and desmoglein) and gap junctions (containing connexins) (Stromer, 1995). The 
nucleus of each cardiomyocyte is centrally located but some have several nuclei that are 
scattered between myofibrils and immediately beneath the sarcolemma. Cardiomyocytes also 
contain many mitochondria which generate the heart’s energy in the form of adenosine 
triphosphate (ATP) (Opie, 1991). 
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Figure 1.3 Schematic representation of a muscle fibre. This diagram shows the arrangement of 
myofibrils and other components of the muscle fibre. Taken from Saladin, 1996.  
 
 
The myofibrils, which are the contractile elements of the cardiomyocytes, are cylindrical in 
shape and 1-2μm in diameter (Fig. 1.3). They are striated in appearance and this is caused by 
the presence of repeating contractile units (sarcomeres) in each myofibril (Ganong, 1991; 
Opie, 1991). When viewed under the microscope, each sarcomere contains a series of broad 
light and dark bands. The sarcomeres are separated from one another by Z lines (Z bands or Z 
disks) which appear as a dense line in the centre of each light band (Opie, 1991). The Z-disc 
proteins include α-actinin, filamin, nebulette, telethonin, and myotilin. 
 
The sarcomere consists of two chief contractile filaments, namely, the thick and thin filaments 
(Fig. 1.4) (Rhoades and Pflanzer, 1996). The thick filaments consist of myosin, myosin-
binding proteins C (MyBP-C), H (MyBP-H), and X (MyBP-X), with myosin being the 
primary structural component (Huxley and Brown, 1967). The thin filaments consist mainly 
of actin which is attached to the Z disk at either end of the sarcomere and held in a square 
lattice arrangement by other proteins including alpha (α)-actinin (Alberts et al., 1994). The 
actin is associated with accessory proteins which include α-tropomyosin (α−Τm), and the 
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troponin complex, which is composed of troponin C (TnC), troponin I (TnI), and troponin T 
(TnT) (Fig. 1.5). Alpha-tropomyosin is a rod-shaped molecule that binds in the groove of the 
actin helix. The troponin complex, on the other hand, is anchored to α-Tm predominantly by 
TnT, and to a lesser extent, by TnI where TnC interacts with both TnT and TnI (Alberts et al., 
1994) (Fig 1.5). Thick and thin filaments overlap in some regions of the sarcomere forming 
an anisotropic (A)-band with isotropic (I)-bands on either side, which contain only actin 
filaments. In the centre of the A-band, there is a clear zone known as the H zone which 
contains myosin only. Each H zone contains a central dark region, the M line, which contains 
titin and other M-line proteins (Trinick and Lowey, 1977) (Fig. 1.3 and Fig. 1.4). 
 
 
Figure 1.4 Schematic representation of cardiac myocyte structure. The sarcomere consists of 
interdigitating thick and thin filaments and is the fundamental structural and functional unit of cardiac 
muscle. Sarcomeres are connected to the sarcolemma, extracellular matrix, and nucleus by a complex 
network of cytoskeletal proteins. Taken from Towbin and Bowles 2002 
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The myosin extends from the centre of the sarcomere in either direction towards the Z disks 
and is connected to the Z disks by a giant protein, titin, which extends along the thick filament 
to the H zone (Fig. 1.4) (Opie, 1991). Titin, together with myomesin and nebulin, form the 
sarcomeric cytoskeleton that supports the thick and thin filaments. Titin gives elasticity to the 
cardiac myofibrils and also contributes to the sarcomere assembly and organisation (Fürst et 
al., 1988, Whiting et al., 1989). Nebulin and titin form a network of fibres associated with 
myosin and actin (Alberts et al., 1994). 
 
 
 
Figure 1.5 Schematic illustration of the troponin complex attachment to α-Tm. Taken from 
http://www.embl.de/~wendt/ troponin.html. 
 
The sarcomeres are connected to each other, the sarcolemma and the neighbouring 
cardiomyocytes by a complex network of proteins that form the cytoskeleton (Alberts et al., 
1994; Opie, 1991). The cytoskeleton provides structural support for subcellular structures and 
transmits mechanical and chemical signals within and between cells. It positions other protein 
complexes and organelles, and also provides communication paths between them. The 
cytoskeleton is composed of three types of filaments, namely, microfilaments, microtubules, 
and intermediate filaments (Alberts et al., 1994; Opie, 1991). These filaments constitute 
different protein subunits: nonsarcomeric gamma (γ)-actin for microfilaments, tubulin for 
microtubules, and a family of related fibrous proteins such as desmin, vimentin and ankyrin 
for intermediate filaments. The γ−actin forms a complex network linking the sarcomere via α-
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actinin to various components of the costameres. Desmin filaments surround the Z disc 
connecting adjacent Z discs and forming lateral connections to subsarcolemmal costameres. 
 
The cytoskeletal network in the sarcolemma and the sarcomeric apparatus are linked by 
costameres, rib-like structures which form subsarcolemmal components (Pardo et al., 1983; 
Koteliansky and Gneushev, 1983; Shear and Bloch, 1985). Costameres are located in a 
periodic, gridlike pattern, in the level of Z lines and overlying the I bands along the 
cytoplasmic side of the sarcolemma. They were initially thought to contain vinculin only but 
were later reported to also include other proteins: talin (Belkin et al., 1986), zyxin (Beckerle, 
1986), paxillin (Turner et al., 1990), spectrin (Repasky et al., 1982; Nelson and Lazarides, 
1983; Craig and Pardo, 1983; Messina and Lemanski, 1989), γ-actin (Craig and Pardo, 1983), 
α-actinin (McGregor et al., 1994; Pavalko et al., 1991), fimbrin (Bretscher and Weber, 1980), 
tensin (Bockholt et al., 1992), intermediate filament proteins (Lazarides, 1978; Granger and 
Lazarides, 1978; Price and Sanger, 1979; Craig and Pardo, 1983), and clathrin (Kaufman et 
al., 1990). These proteins are grouped into three multimolecular complexes: the focal 
adhesion-type membrane skeleton (vinculin, talin, tensin, paxillin, α-actinin, and zyxin), the 
spectrin-based membrane cytoskeleton (spectrin, ankyrin, and γ-actin), and the 
dystrophin/dystrophin-associated glycoprotein (DAG) complex. The DAG complex is the 
association of dystrophin with a large complex of proteins and glycoproteins called 
dystrophin-associated proteins (DAP) (Berthier and Blaineau, 1997). The DAP complex 
consists of one extracellular protein (α-dystroglycan), six integral proteins (β-dystroglycan, 
α-, β-, γ- and δ-sarcoglycan; and a 25 kDa protein) and three cytoplasmic proteins (α- and β-
syntrophins, and dystrobrevin) which are grouped into three subcomplexes, namely, the 
dystroglycan, sarcoglycan and syntrophin subcomplexes (Yoshida and Ozawa, 1990). 
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1.1.4 Mechanism of cardiomyocyte contraction 
The biochemical basis of muscle contraction involves enzymatic and physical properties of 
actin, myosin, and six accessory proteins (α-actinin, β-actinin, tropomyosin, troponin 
complex, cMyBP-C, and M line proteins) of thin and thick filaments (Albert et al., 1994). 
Myosin molecules are long thin fibrous proteins with each molecule consisting of 6 subunits: 
two myosin heavy chains (MHC) and two pairs of smaller light chains (two essential and two 
regulatory light chains). The MHC folds into the globular catalytic domain and extends as an 
α-helical rod through the light chain domain. The globular domain can be proteolytically 
cleaved into subfragment 1 (S1) which is futher divided into a 25, 50, and 20-kDa fragments, 
and subfragment 2 (S2). Each myosin head or subfragment 1 (S1) contains a catalytic 
adenosine triphosphatase (ATPase)- and actin binding sites (Fig. 1.6) (Rayment et al., 1993). 
The S2 subfragment links the two heads and extends into a long rod segment that is bound 
into the shaft of the thick filament. 
 
Muscle contraction is initiated when the muscle gets signals from the motor nerve which 
subsequently triggers an action potential in the sarcolemma (Alberts et al., 1994). The action 
potential spreads rapidly into the T-tubules, and is then relayed across a small gap (junctional 
region) to the sarcoplasmic reticulum (SR). The junctional region contains calcium channels 
that extend from the SR membrane to make contact with the T-tubule membrane on the other 
side. In the T-tubule membrane, the voltage-sensitive channels are activated by the action 
potential, and the calcium channels are triggered to release more calcium ions (Ca2+). Calcium 
ions are released from their stores in the SR into the cytosol, and myofibril contraction is 
initiated. During diastole, the interaction between actin and myosin is inhibited by binding of 
TnI to the actin-Tm complex, but Ca2+ release from the SR and its binding to TnC causes a 
conformational change that weakens the interaction between TnI and actin-αTm, and 
strengthens TnI-TnC interaction (Solaro and van Eyk, 1996). These changes release the thin 
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filament from its inhibitory state, inducing actin-myosin interaction and force generation. A 
reduction in Ca2+ concentration ([Ca2+]i) causes a dissociation of Ca2+ from TnC and restores 
the relaxed state. 
 
The myofibril contraction is a result of the interaction between myosin heads and adjacent 
actin filaments, during which the ATPase in the myosin head hydrolyses ATP (Alberts et al., 
1994). The ATP hydrolysis, which is followed by dissociation of the tightly bound adenosine 
diphosphate (ADP) and a pyrophosphate (Pi), produces an ordered series of allosteric changes 
in the myosin conformation. This results in energy release which is coupled to the movement 
of myosin head along the actin filament. A “sliding filament” model, was proposed by Huxley 
in 1957, which explains the generation of force by the sliding movement of the thick filament 
relative to thin filaments. This movement is mediated by the cyclical attachment and 
detachment of myosin “cross bridges” to actin. The model was modified to a “swinging cross-
bridge” model (Fig. 1.6) (Huxley, 1969; Lymn and Taylor, 1971), which postulates that a 
swinging movement of the myosin head is a determining factor for its progression along the 
thin filament. The model that is currently used is the “lever-arm” model, a modification of the 
“swinging cross-bridge” model (Fig. 1.6) (Rayment et al., 1993). The “lever-arm” model 
states that the catalytic domain remains at a constant position as the elongated light chain 
domain swings, magnifying conformational changes within the myosin head which 
accompany ATP hydrolysis. The swinging movement of the myosin tail produces a power 
stroke. The intermolecular changes of the myosin head (the opening and closing state) link the 
actin and ATP-binding sites and help the nucleotide pocket to release Pi which signals the 
onset of the power stroke (Yount et al., 1995). 
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Figure 1.6 Schematic representation of a myosin molecule (a) and alternative early models of 
swinging crossbridge cycle (b-d) of muscle contraction. S1 and S2-subfragments 1 and 2, LCD- light 
chain domain, CD- catalytic domain (see the text for details). b) the “swinging crossbridge” model 
proposed by Huxley in 1969, (1) a myosin head attaches to actin at a 90° angle, (2) and the whole 
head swings to a 45° angle. c) A myosin head attaches to actin at one angle (1) and produces force by 
sliding over the actin binding site (2) to the end of the power stroke (3) (Huxley, 1974). d) The “lever 
arm model”: a myosin head is attached to actin at a stable position (1) and bends in the middle (2) 
producing force and changing the crossbridge angle (3) (Rayment et al., 1993). Taken from Reedy, 
2000. 
 
Calcium regulates muscle contraction by binding to TnC after it is released from the SR 
causing a conformational change that weakens the interaction between TnI and actin-
tropomyosin, and strengthens TnI-TnC interaction (Solaro and van Eyk, 1996; Bers, 2000). 
The action potential from the motor nerves to the sarcolemma stimulates Ca2+ influx by direct 
entry into the cell via voltage-gated L-type channels, and, to a lesser extent, via Na+/Ca2+ 
exchanger. Inside the cell, Ca2+ binds to cytosolic buffers which include TnC. Calcium influx 
triggers Ca2+ release from the SR to the cytosol through ryanodine and inositol 1,4,5-
trisphosphate receptors and, subsequently, myofibril contraction. The extent of cardiac 
contraction is determined not only by the entry of Ca2+ from the extracellular fluid and the 
SR, but also by the buffering capacity of the cell (Bers, 2000). During relaxation, Ca2+ is 
removed from the cytosol by the SR Ca2+-ATPase (SERCA2a), sarcolemmal Na+/Ca2+ 
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exchanger, sarcolemmal Ca2+-ATPase, and mitochondrial Ca2+ unipoter. The [Ca2+]i is 
maintained by a complex network of positive and negative feedback mechanisms. The 
dependence of force on Ca2+ is expressed as a function of free [Ca2+]i, but this relationship 
does not directly indicate the amount of Ca2+ required to activate myofilaments, since changes 
in myofilament sensitivity to Ca2+ occur. Changes in myofilament sensitivity are brought 
about by protein kinase A which phosphorylates TnI. It is also decreased by low pH, and 
reduced sarcomere length (Bers, 2000). 
 
Calcium also affects the conformation of the thin filament which, as a result, exists in three 
activation states (Wannenburg et al., 2000; Solaro and Van Eyk, 1996; McDonald and Moss, 
2000). When Ca2+ is not bound to TnC, the thin myofilament is in a “blocked” (off) state and 
the cross-bridge binding is unable to occur. In a “closed” (off) state, Ca2+ is bound to TnC but 
there is no strong cross-bridge binding; in an “open” (on) state, Ca2+ is bound to TnC and 
cross bridges are strongly bound. According to this model, Ca2+ may determine both whether 
or not cross-bridges bind and the strength of binding. It has also been proposed that changes 
in Ca2+ activation may alter the number of cross-bridges attached, and the kinetics of cross-
bridge attachment and detachment (Wannenburg et al., 2000; Solaro and Van Eyk, 1996; 
McDonald and Moss, 2000). 
 
Other regulators of muscle contraction include cMyBP-C and myosin light chains (MLC) 
(Poetter et al., 1996; Sanbe et al., 2000; Gautel et al., 1995). Cardiac MyBP-C may 
participate in the adrenergic regulation of cardiac contraction. Ultrastructural studies have 
shown that phosphorylation of cMyBP-C by cAMP-dependent protein kinase extends myosin 
cross-bridges from the backbone of the thick filament and changes their orientation. The 
phosphorylation status of cMyBP-C is a determinant of rigidity and attachment rates of cross-
bridges, and Ca2+ sensitivity of force production (Kunst et al., 2000; Weisberg and Winegrad, 
  
16
1998). The myosin essential and regulatory light chains (MELC and MRLC) bind to the α-
helical lever arm of the myosin cross-bridge and influence force production by modulating 
cross-bridge kinetics (Poetter et al., 1996; Sanbe et al., 2000). Numerous extrinsic factors 
including neurohomoral, endocrine, and haemodynamic factors also influence cardiac 
contraction in vivo. 
 
Calcium dysregulation has been reported to be one of the possible unifying abnormalities 
caused by HCM-associated mutations in sarcomeric proteins that result in the hypertrophic 
response. Calcium is predicted to link sarcomere force production to myocyte growth by 
activating a complex cascade of signalling pathways (Molkentin et al., 1998) (section 1.5.4). 
Thus, any proteins involved in Ca2+ regulation and those that are downstream signalling 
components are plausible candidates for dissection of the molecular causes of HCM, as well 
as DCM and PFHBII. 
 
1.2 The Human Genome Project (HGP) and Bioinformatics  
Sequencing of the human genome has provided insight into various biological processes and 
serves as a resource of all human genes, and has allowed the identification of genetic causes 
of many inherited disorders. As this study is focused on identifying genetic causes and 
modifiers of PFHBII and HCM, respectively, it is relevant to mention the progress in the 
sequencing of the human genome and integration of its data into various databases. 
 
1.2.1 The HGP 
The Human Genome Project (HGP) is an informational collaboration started in the mid 1980s 
with the primary goal of sequencing the entire human genome (Dib et al., 1996). The HGP 
was officially initiated in the United States (US) by late 1980s under the direction of the US 
Department of Energy (DOE) and National Institute of Health (NIH). During the course of the 
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initiative, two groups became competitively involved in the sequencing of the genome using 
different methodologies and collecting separate data sets (International Human Genome 
Sequencing Consortium, 2001; Venter et al., 2001). The International Human Genome 
Sequencing Consortium released the first data set from the human genome (draft human 
genome sequence), which covered most of the genome, for public use in June 2000. The data 
was made available to the scientic research community through public databases such as the 
National Centre for Biotechnology Information (NCBI), the Sanger Centre (Ensembl genome 
browser) and the University of Santa Cruz Centre (UCSC). 
 
The three centres continued to update the human genome sequence data as it was 
continuously generated (Fig. 1.7). In April 2003, the first finished reference sequence for the 
human genome was released and consisted of 24 finished chromosomes of 2.9 billion bases 
and covered about 99% of the gene-containing DNA (Collins et al., 2003). Small updates to 
the assembly were also continuously released after the announcement of the finished 
reference sequence, as the complex regions were refined and small gaps closed between the 
large stretches of contiguous sequences (contigs). The finished reference human sequence, 
along with the results of its analysis and gene annotations, is available for viewing and 
downloading in various databases, namely, NCBI, the Sanger Centre and UCSC (appendix I). 
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Figure 1.7 Illustration of the progress of the HGP from 12 December 2000 to July 2003. The 
regions of the genome are arranged according to the dates they were released: NCBI34- July 2003, 
NCBI33- 14 April 2003, NCBI31- November 2002, NCBI30- 24 June 2002, NCBI29- 5 April 2002, 
NCBI28- 24 December 2001, NCBI26- 24 September 2001, UCSC hg8- 6 August 2001, UCSC 
(ensemble 1.1.0)- 1 April 2001, USCS (ensemble 1.0.0)- 12 December 2000. The completeness of the 
chromosomal regions is indicated by different colour and these regions are measured by N50 length. 
Taken from http://www.ensembl.org/Homo_sapiens/stats/status.html. 
 
 
1.2.2 Bioinformatics 
The data generated through sequencing of the human genome have accumulated over the 
years (from the time of the initial sequencing), necessitating the development of technologies 
that can be used to analyse the sequence and apply it in various biological fields. Through the 
development of these new technologies, which include laboratory techniques and computer 
programs, biology and computer were combined to form one discipline termed 
bioinformatics. The new technologies (also referred to as bioinformatics tools) were 
integrated into various databases according to a particular biological segment that needs to be 
NCBI34 NCBI33 NCBI31  NCBI30  
NCBI29  NCBI28 NCBI26  UCSC hg8 
UCSC (ensembl 1.1.0) UCSC (ensembl 1.0.0) 
 None of bin in golden path -
Less than 50% of bin in golden path
More than 50% of bin in golden path
N50 length > 10kb
N50 length > 100kb
N50 length > 500kb
N50 length > 1mb
N50 length > 5mb
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addressed. Approximately 548 databases are collectively listed in Nucleic Acid Research 
(NAR) issues, and the list, together with the short summary and updates of each database, is 
also freely accessable through the NAR website at http://www.nar.oupjounarls.org 
(Baxevanis, 2001; Galperin, 2004). 
 
Three sequence data centres, NCBI, Ensembl and UCSC, were used in the present study to 
access published information about the genetically inherited disorders under study, and genes 
from which the plausible candidates were selected for the analysis of PFHBII-causing and 
HCM-causing and/or modifying mutations. These three centres are focusing on the detailed 
annotation of the human genome. In addition, these databases also contain a vast amount of 
additional annotations for features such as repetitive DNA, expressed-sequence tags (ESTs), 
CpG islands, and single nucleotide polymorphisms (SNPs). Programs are available within 
these centres that facilitate data input, quality control, data retrieval, presentation, sequence 
comparison and functional analysis. 
 
1.3 Cardiac conduction system disorders 
1.3.1 Progressive Familial Heart Block-type II (PFHBII) 
The first facet of the study involved the search for the gene which causes PFHBII, a disease 
that was originally described as a cardiac conduction system disorder of unknown aetiology, 
which is inherited in an autosomal dominant manner. The disorder was identified in a South 
African Afrikaner family (Fig. 1.8) whose ancestors were traced to a Dutch immigrant who 
arrived in South Africa in 1713 (Brink and Torrington, 1977).  
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Figure 1.8 A four-generation pedigree in which PFHBII was identified and described (Brink and 
Torrington, 1977). Twenty four members of the family were clinically evaluated in the original study 
and 10 of them were affected. 
 
The disease was initially characterised by isolated sinus bradycardia (SB), isolated left 
posterior hemiblock associated with syncopal episodes, Stokes Adams seizures (light 
headedness) or complete heart block with narrow QRS complexes (Brink and Torrington, 
1977). Among members of the PFHBII family that were evaluated in the initial study and 
additional members who were examined in a later study, several individuals presented a 
phenotype with a characteristic progression from conduction defects to DCM, demonstrating 
that cardiomyopathy is one of the clinical features of the disorder (Fernandez et al., 2004). 
The genetic cause of PFHBII has not been identified yet, but linkage studies performed in the 
affected family mapped the disorder to a locus on chromosome 1q32.2-32.3 that is 
encompassed by markers D1S70-D1S505 (Fig. 1.9) (P. Fernandez, personal communication).  
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Figure 1.9 An ideogram of chromosome 1. The PFHBII locus is flanked by markers D1S70 and 
D1S505. The markers are localised at position 1q32.2-q32.3. 
 
 
Other familial forms of inherited cardiac conduction system disorders have been described, 
which may give an insight into the pathogenesis of PFHBII, and these include progressive 
cardiac conduction disorder (PCCD) or Lenègre disease (Lev et al., 1970; Lenègre and 
Moreau 1963), non-progressive cardiac conduction disorder (CCD) (Tan et al., 2001), 
progressive familial heart block type I (PFHBI) (Brink and Torrington, 1977) and isolated 
cardiac conduction disorder (ICCD) (Stephan, 1978).  
 
PFHBI and ICCD 
PFHBI (MIM 113900) was identified in a Caucasian South African family and described as 
an autosomal dominantly inherited cardiac bundle-branch disorder characterised by RBBB 
that may progress to complete heart block (Brink and Torrington, 1977; Van der Merwe et al., 
1986). ICCD is characterised by either a complete or incomplete RBBB with or without QRS 
frontal-axis deviation and was identified in a Lebanese family (de Meeus et al., 1995). In 
p arm 
q arm 
D1S70 (1q32.2) 
D1S505 (1q32.3) 
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1995, Brink and co-workers reported linkage analysis, which mapped PFHBII to chromosome 
19q13.3. In the same year (1995), de Meeus et al., reported mapping ICCD to chromosome 
19q13.3, a region that overlaps with the PFHBI locus. Consequently, the groups (Brink and 
Stephen, respectively) who described the two disorders formed a brief collaboration and 
suggested that PFHBI and ICCD are likely to be one clinical entity caused by the same, as 
yet, unidentified gene.  
 
PCCD and non-progressive CCD 
PCCD (MIM 600163) is characterised by progressively deteriorating cardiac conduction 
through the bundle of His-Purkinje system causing a LBBB or RBBB that eventually leads to 
complete AV block and sudden death (Lev et al., 1970; Lenègre and Moreau 1963). Little 
was known about the molecular cause of PCCD until Schott and colleagues (1999) performed 
a linkage analysis in French and Dutch families with PCCD and reported a causative locus on 
chromosome 3p21. Subsequently, they reported causative mutations identified in a Na+ 
channel gene (SCN5A), which plays a role in cardiac excitability by allowing Na+ ion influx 
that further depolarises excitable myocytes (Hodgkin et al., 1952). Interestingly, a few years 
later Tan et al., (2001) identified a mutation in SCN5A that causes the non-progressive CCD 
that is characterised by broad P waves and QRS complexes, first-degree heart block and 
severe SB. These findings by Schott et al., (1999) and Tan et al., (2001) were interesting as 
other mutations in SCN5A were reported to cause three types of inherited arrhythmias known 
as long QT type 3 (LQT3) (Wang et al., 1995), Brugada syndromes (Bezzina et al., 1999; 
Naccarelli et al., 2002; Baroudi et al., 2001) and idiopathic ventricular fibrillation (IVF) 
(Chen et al., 1998). 
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LQT3, Brugada syndromes and IVF 
LQT3 (MIM 603830) is a disorder of repolarisation that is characterised by prolongation of 
the QT interval on the surface ECG, relative bradycardia, T wave abnormalities, and episodes 
of ventricular tachyarrhythmias (Wang et al., 1995). Brugada syndrome (MIM 601144) is 
characterised by the elevation of the right precardial ST-segment and ventricular fibrillation 
(Brugada and Brugada, 1992). Although Brugada syndrome is an arrhythmic disorder, it is 
accompanied by RBBB, which is indicative of cardiac conduction defects (Schwartz et al., 
1995; Schwartz et al., 1997). Brugada syndrome is also accompanied with ventricular 
fibrillation, however, a SCN5A-missense mutation was identified in a Japanese individual 
who exhibited IVF but without a typical ECG pattern of the Brugada syndrome (Akai et al., 
2000). PCCD, LQT3 and Brugada syndrome have been reported to be caused by different 
mutations in SCN5A, however, several studies have demonstrated that some of the mutations 
can result in either LQT3, the Brugada syndrome or PCCD (Bezzina et al., 1999; Veldkamp 
et al., 2000; Grant et al., 2002). 
 
Pathophysiology of PCCD, LQT3 and Brugada syndrome 
Functional studies of Na+ channels suggest that Brugada syndrome and PCCD mutations 
reduce the magnitude of Na+ current (Dumaine et al., 1999; Veldkamp et al., 2000; Deschenes 
et al., 2000), whereas LQT3 mutations cause excessive Na+ current resulting in prolongation 
of action potential duration and the QT interval (Wang et al., 1995; Bennett et al, 1995; Priori 
et al., 1999). However, mutations that cause PCCD only result in slow conduction without the 
ST-T wave changes that characterise Brugada syndrome (Tan et al., 2001). Further analysis of 
the effect of the disease-associated SCN5A mutations is required to elucidate the diverse 
functional behaviour of the channel that may evoke a spectrum of abnormal cardiac 
excitability, from conduction disease to sudden death.  
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Mutations in a homeobox protein Nkx2.5 gene (NKX2.5), have also been reported to cause an 
autosominal dominantly inherited congenital heart disease with or without progressive AV 
block. NKX2.5 encodes a transcription factor that is important in early stages of heart 
development, as well as maturation (Chen and Schwartz, 1996; Durocher et al., 1997; Tanaka 
et al., 1998). The most common phenotypes that result from NKX2.5 mutations are AV block 
and atrial septal defects (ASD), but ventricular septal defect (VSD), tetralogy of Fallot (TOF) 
and tricuspid valve abnormalities are also included (Benson et al., 1999). Several mutations 
have been reported in NKX2.5, which are distributed throughout the molecule (Benson et al., 
1999; Goldmuntz et al., 2001; Ikeda et al., 2002). However, the exact mechanisms by which 
these mutations cause congenital heart disease are still unclear. Some mutations are predicted 
to reduce the DNA binding affinity of NKX2.5, resulting in a loss of transcription activation 
function of the protein, whereas other mutations decrease the ability of the molecule to form 
dimers (Kasahara et al., 2000; Zhu et al., 2000). Further analysis of NKX2.5 mutations may 
lead to better understanding of the mechanisms by which the mutations cause congenital heart 
disease. 
 
1.4 Dilated cardiomyopathy (DCM) 
Dilated cardiomyopathy is a cardiac muscle disorder that is characterised by genetic 
heterogeneity. The disorder is one of the PFHBII clinical features and, as it has been widely 
studied, DCM gave a platform for investigating a molecular cause of PFHBII. Thus, clinical 
features and genetic causes of DCM will be discussed in the following subsection. 
 
1.4.1 Clinical characterisation of DCM 
Dilated cardiomyopathy is a common complex myocardial disorder characterised by 
increased ventricular chamber size (dilation) (Fig. 1.10) and diminished systolic function (Dec 
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and Fuster, 1994; Report by the WHO/ISFC, 1996). Impaired systolic function triggers 
complex neurohormonal responses that at first are compensatory responses but which 
ultimately worsen resulting in the onset of heart failure and sudden death, or necessitating 
cardiac transplantation. Myocyte disarray and increased interstitial fibrosis are not 
morphological and histopathological features of DCM, as is the case in HCM. Clinical 
symptoms include shortness of breath, fatigue, intolerance of physical exertion, fainting, light 
headedness, sweating at rest and sudden death (Abelman and Lorrell, 1989). Although 
improvement in medical therapy has been reported, DCM continues to be a lethal disease with 
a 5-year mortality rate of 50 to 75% (Abelman and Lorell, 1989). Epidemiological data 
indicates that about 36.5 individuals in 100 000 are affected (Gillum, 1986; Michels et al., 
1992; Grünig, 1998). In approximately 50% of DCM cases the aetiology is unknown, 
however, myocarditis, toxins, ischaemia, metabolic causes, viral infections, valvular heart 
disease, coronary heart disease and autoimmunity are recognised as causes. In approximately 
25 to 30% of the cases, the disease is caused by inherited gene defects (Grünig et al., 1998; 
Michels et al., 1992). However, age-related penetrance and nonpenetrance confound the 
picture and lead to an underestimation of the prevalence of the condition. 
 
 
Figure 1.10 A heart from an individual with dilated cardiomyopathy. The dilated left ventricle is 
indicated by an arrow. Abbreviations: LV- left ventricle, RV- right ventricle. Taken from 
www.hopkinsmedicine.org/cardiology/ heart/photographs.html. 
 
 
LV 
RV 
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1.4.2 Genetics of DCM 
Molecular genetic studies performed in DCM-affected families demonstrated four forms of 
transmission of the disease: autosomal dominant, autosomal recessive, X-linked and maternal, 
with the autosomal dominant form being the predominant one affecting individuals of all ages 
(Richardson et al., 1996; Grünig et al., 1998; Bowles et al., 1996). Linkage analyses provided 
the first evidence of genetic heterogeneity by identification of several disease loci that were 
associated with distinct DCM clinical phenotypes such as pure DCM, DCM associated with 
conduction system disease and/or skeletal myopathy and DCM with sensorineural deafness 
(Grung et al., 1998; Mestroni et al., 1999) (table1.1). Subsequently, DCM-causing mutations 
were identified in thirteen genes that encode cytoskeletal (Li et al., 1999; Tsubata et al., 2000; 
Olson et al., 2002, Franz et al., 2000; Arbustini et al., 2000; Muntoni et al., 1995; Towbin et 
al., 1993), sarcomeric (Kamisago et al., 2000.; Regitz-Zagrosek et al., 2000; Olson et al., 
1998; Olson et al., 2001; Siu et al., 1999; Gerull et al., 2002), mitochondrial (Bione et al., 
1996; D’Adamo et al., 1997; Bleyl et al., 1997) and nuclear proteins (Kass et al., 1994; Fatkin 
et al., 1999; Bonne et al., 1999; Genschel and Schmidt, 2000; Muchir et al., 2000). 
 
1.4.3 Mechanisms underlying the pathogenesis of DCM 
The mechanisms underlying DCM-causing mutations have not been extensively studied, 
however, identification of causal mutations in genes encoding cytoskeletal, sarcomeric and 
nuclear proteins suggested three possible mechanisms: defective force transmission (Towbin 
et al., 1999), defective force generation and disruption of the nuclear structure and function 
(Seidman and Seidman, 2001; Fatkin and Grahm, 2002).  
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Table 1.1. Genetic locus heterogeneity underlying dilated cardiomyopathy and conduction disorders. 
Disorder Causative gene Locus Reference 
DCM only    
 TNNT2 1q32 Kamisago et al., 2000. 
 MYBPC3 11p11 Regitz-Zagrosek et al., 2001. 
 MYH7 14q12 Kamisago et al., 2000. 
 ACTC 15q14 Olson et al., 1998. 
 TPM1 15q22 Olson et al., 2001. 
 TTN 2q31 Siu et al., 1999; Gerull et al., 2002 
 VCL 10q22-q23 Olson et al., 2002 
 PLN 6p22.1 Schmitt et al., 2003 
 DES 2q35 Li et al., 1999 
 SGCD 5q33 Tsubata et al., 2000. 
DCM + cardiac conduction 
system disorder + skeletal 
myopathy 
LMNA 1p1-q21 Kass et al., 1994; Fatkin et al., 1999; 
Bonne et al., 1999; Genschel and 
Schmidt, 2000; Muchir et al., 2000. 
X-linked DCM DMD Xp21 Franz et al., 2000; Arbustini et al., 
2000; Muntoni et al., 1993; Towbin et 
al., 1993. 
X-linked infantile DCM G4.5 Xq28 Bione et al., 1996; D’Adamo et al., 
1997; Bleyl et al., 1997 
Brugada syndrome, and LQT3 SCN5A 3p21-24 Jiang et al, 1994; Wang et al., 1995 
Abbreviations: ACTC- cardiac actin gene; DCM- dilated cardiomyopathy; DES- cardiac desmin gene; cardiac 
dystrophin gene (DMD); G4.5- cardiac tafazzin gene; LGMD2F- limb girdle muscular dystrophy; LMNA- lamin 
A/C gene; LQT3- chromosome 3-linked Long QT syndrome; MYBPC3- cardiac myosin binding protein C gene; 
MYH7- cardiac myosin heavy chain gene; RWS- Romano-Ward syndrome; SCN5A- sodium channel, voltage-
gated type 5, alpha subunit gene; SGCD − δ-sarcoglycan gene; TNNT2- cardiac troponin T gene; TPM1- cardiac 
tropomyosin gene; TTN- cardiac titin gene; VCL- cardiac metavinculin gene. 
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Defective force transmission 
The “defective force transmission” hypothesis is based on the fact that DCM-causing 
mutations were identified in dystrophin, desmin, vinculin and δ-sarcoglycan, which are 
among structural proteins that form the extrasarcomeric cytoskeleton and the DAG complex 
(Alberts et al., 1994; Opie, 1991). The DAG complex forms part of the subsarcolemmal 
domains, the costameres, which are the interconnection sites between various cytoskeletal 
networks that link the sarcomere (contractile unit of the muscle) and the sarcolemma (section 
1.1.3). The cytoskeleton transmits force generated during muscle contraction from the 
sarcomere to the extracellular matrix and protects myocytes from the external mechanical 
stress (Pardo et al., 1983; Koteliansky and Gneushev, 1983). Thus, abnormalities in 
cytoskeletal proteins and those that form the costameres are proposed to cause DCM through 
ineffectual propagation of force from the sarcomere to the extracellular matrix and/or 
resistence to mechanical stress. The pathogenesis may be a result of either a dysfunctional 
protein or abnormal interaction with other proteins. This concept is supported by the effect of 
dystrophin mutants on the DAG complex. The truncated dystrophin, when incorporated into 
the complex, alters the assembly of the sarcoglycan complex (Franz et al., 2000). It has also 
been noted that two vinculin mutations (Leu954del and Arg975Trp mutations) result in 
disrupted metavinculin-mediated organisation of actin filaments and abnormal interaction of 
metavinculin with phospholipids (Olson et al., 2002). Furthermore, the location of two DCM-
causing mutations on the immobilised end of actin predicts a deficit in actin-cytoskeletal 
interaction, which may interfere with force transmission from the sarcomere to the 
extracellular matrix (Olson et al., 1998). 
 
Defective force generation 
The “defective force generation” hypothesis is based on the identification of DCM-causing 
mutations in four genes encoding sarcomeric proteins, namely, β-MHC, α-Tm, TnT and 
cMyBP-C (Olson et al., 1998; Kamisago et al., 2000; Regitz-Zagrosek et al., 2000; Olson et 
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al., 2001; Fatkin and Grahm, 2002). The β-MHC chain is one of the components of the 
contractile unit, which, by interacting with actin generates force and results in muscle 
contraction (Huxley and Brown, 1967) (section 1.1.3). Alpha-tropomyosin and TnT are 
among the proteins that constitute the troponin-tropomyosin complex, a Ca2+-sensitive switch 
that regulates actin-myosin interaction (Alberts et al., 1994). Therefore, any abnormalities in 
these proteins may interfere with actin-myosin interaction, and, hence, force generation. The 
concept is supported by identification of DCM-causing mutations in actin-binding domains of 
both α-Tm and TnT, which, as a result, interefere with actin-myosin interaction (Kamisago et 
al., 2000; Olson et al., 2001). Furthermore, atomic structures and biochemical studies have 
been useful in elucidating the functional effects of TnT mutations (Rayment et al., 1995). A 
deletion of one of the conserved lysine residues was identified in TnT that weakens the 
complementary ionic interaction with acidic residues in troponin C, the binding partner of 
TnT (Filatov et al., 1999). Consequently, the calcium-stimulated actin-myosin ATPase 
activity is altered diminishing the energy production for actin-myosin detachment and 
reattachment, and, as a result, reducing the contractile force within the sarcomere. 
 
Disruption of the nuclear structure and function 
Another possible underlying mechanism is disruption of the nuclear structure and function, 
which is based on the premise that DCM-causing mutations were identified in lamin A/C gene 
(LMNA) (Fatkin et al., 1999) that encode components of the nuclear envelop called lamins A 
and C (Aaronson and Globel, 1975). Nuclear lamins contribute to the structural integrity of 
the nuclear envelope and provide mechanical support for the nucleus (Gerace, 1986). Thus, 
DCM-causing mutations identified in LMNA are predicted to cause disorganisation of nuclear 
structure by altering the assembly of dimers and of complex filaments (Fatkin et al., 1999; 
Raharjo et al., 2001). Altered transcription regulation is also a possible mechanism that can 
result in DCM, as predicted by one of the roles of lamins in transcription regulation through 
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the molecule’s binding to chromatin and several transcription factors (Stuurman et al., 1998). 
Further investigation on the mechanisms by which LMNA mutations cause human disease will 
provide insight into the biology of lamins and their importance in the nucleus and viability of 
cells. 
 
1.5 Hypertrophic cardiomyopathy (HCM) 
The second facet of the study involved identification of novel HCM main locus genes and/or 
HCM modifying genes which may affect the phenotypic expression of this disorder. 
Phenotypic variability has been noted among HCM-affected individuals carrying identical 
causal mutations (Fananapazir and Epstein, 1994; Marian et al., 1995; Niimura et al., 1998). 
Although diversity in causal mutations has been reported to contribute to this variability, other 
factors can also influence the disease expression. Therefore, in the following section a 
summary of HCM-genetic causes, their biophysical properties and clinical outcomes will be 
given. 
 
1.5.1 Clinical characteristics of HCM 
Hypertrophic cardiomyopathy was recognised as early as 1869 (Hallopeau, 1869) but its 
clinical features were only described in 1950 (Teare, 1958). The disorder is characterised by 
left and/or right ventricular hypertrophy which is usually asymmetric and can affect different 
regions of the ventricular wall (Fig. 1.25) (Report of the WHO/ISHF Task force, 1980). The 
interventricular septum is the most commonly affected part (Wigle et al., 1985). Other 
histological features include myofibrillar disarray and interstitial fibrosis. Myocardial 
hypertrophy is either a primary disease of the heart, or an adaptive response secondary to 
haemodynamic disturbances (pressure or volume overload) or endocrine abnormalities.  
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The prevalence of echocardiographically-defined HCM in a general population in the USA 
has been reported to be one affected individual in 500 (Maron et al., 1995), but in South 
Africa the prevalence has not been reported. HCM is clinically heterogeneous with inter- and 
intrafamilial variations ranging from asymptomatic to severe forms with high risk of heart 
failure or sudden death (Maron, 2000). Genotype-positive individuals may be asymptomatic 
or present variable symptoms that include shortness of breath (dyspnoea) and chest pains 
(angina) due to impaired diastolic relaxation of the hypertrophied heart, syncope, embolism, 
congestive heart failure, deprivation of oxygen (myocardial ischaemia), mitral regurgitation, 
arrhythmia and outflow tract obstruction (Brachfeld and Gorlin, 1959; Brent et al., 1960). 
 
 
Figure 1.11. A longitudinal section of a heart. a) a normal heart and b) a hypertrophied heart. The 
hypertrophied interventricular septum and left ventricle are indicated by arrows. Abbreviations: RV- 
right ventricle, IVS- interventricular septum, LV- left ventricle. Taken from 
www.hopkinsmedicine.org/cardiology/ heart/photographs.html. 
 
 
1.5.2. Genetics of HCM 
HCM occurs both in sporadic and familial forms, with more than half of the cases being 
familial (Paré et al., 1961). Familial HCM (FHC) is transmitted in an autosomal dominant 
pattern with one defect in a causative gene reported to be sufficient to cause the disease. 
Linkage analysis has provided insight into the clinical diversity of FHC with subsequent 
b) a) 
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identification of disease loci on chromosome 14q12 (MYH7) (Jarcho et al., 1989), 1q32 
(TNNT2) (Watkins et al., 1993), 15q22 (TPM1) (Theirfelder et al., 1993), 11q11 (MYBPC3) 
(Carrier et al., 1993) (table 1.2). Other genes (ACTC, TNNI3, MYL3, MYL2 and TTN) 
encoding sarcomeric proteins (cardiac actin, TnI, MELC, MRLC and titin) were also 
recognised as rare causes of the disease (Mogensen et al., 1999; Kimura et al., 1997; Poetter 
et al., 1996; Satoh et al., 1999). These findings led to a conclusion that HCM is a disease of 
the sarcomere (reviewed by Seidman and Seidman, 2001). However, HCM-causing mutations 
were later identified in genes that encode nonsarcomeric proteins, namely, a 5’-AMP-
activated protein kinase (AMPK), γ2−subunit-encoding gene (PRAGK2) (Arad et al., 2002; 
Gollob et al., 2001), muscle LIM protein-encoding gene (CRP3) (cytoskeletal protein) (Geier 
et al., 2001) and phospholamban gene (PLN) (sarcoplasmic reticulum protein) (Schmitt et al., 
2003).  
 
More than 250 HCM-causing mutations have been identified in these genes, which account, 
in part, for the clinical diversity of the disease. Mutations in the genes listed in table 1.2 
account for approximately 50-70 % of all cases of FHC and it is assumed that genes, each 
accounting for a small proportion, still remain to be identified (Marian and Robert, 1995). 
Three of the HCM-causative genes predominate, namely β-MHC gene (MYH7), TnT gene 
(TNNT2) and cMyBP-C gene (MYBPC3), and other genes each account for a minority of 
HCM cases (Marian and Robert, 1995). Worldwide, 35% of FHC is caused by mutations in 
MYH7, 20% caused by mutations in MYBPC3, 15% by mutations in TNNT2, and less than 3% 
by mutations in TPM1 (Watkins et al., 1995). The phenotypic expression of the disease is 
measured according to the magnitude and pattern of hypertrophy, the age of onset, the 
incidence of arrhythmias, the histological extent of myofibrillar disarray, the predisposition to 
heart failure and the incidence of sudden death (Braunwald, 2002). However, according to 
genetic analysis performed with South African HCM-affected individuals, founder mutations 
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in MYH7 (Ala797Thr and Arg403Trp) and TNNT2 (Arg92Trp) account for 25% 5% and 11%, 
respectively, of the HCM cases (Moolman-Smook et al., 2000). 
 
 
Table 1.2. HCM-causing chromosomal loci and disease genes  
Disorder Causative 
gene 
Locus Reference 
HCM MYH7 14q12 Geisterfer-Lowrance et al., 
1990; Vikstrom and Leinwand, 
1996. 
 MYBPC3 11p11 Bonne et al., 1995; Watkins et 
al., 1995. 
 TNNT2 1q32 Thierfelder et al., 1994. 
 TNNI3 19q13 Kimura et al., 1997. 
 TPM1 15q22 Thierfelder et al., 1994. 
 MYL2 12q23-q24 Poetter et al., 1996. 
 MYL3 3p21 Poetter et al., 1994. 
 ACTC 15q14 Olson et al., 2000. 
 PLN   
 TTN 2q31 Satoh et al., 1999. 
 CRP3 11p15 Geier et al., 2001. 
HCM+WPW+ 
conduction 
system disorders 
PRKAG2 1q36 Blair et al., 2001; Gollob et al., 
2001; Arad et al., 2002;  
Abbreviations: ACTC- cardiac actin; CRP3- cardiac muscle LIM protein gene; HCM- hypertrophic 
cardiomyopathy; MYBPC3- cardiac myosin binding protein C gene; MYH7- cardiac myosin heavy chain gene; 
PRKAG2- 5’-AMP-activated protein kinase, gamma-2 subunit gene; TNNI3- cardiac troponin I; TNNT2- cardiac 
troponin T gene; TPM1- cardiac tropomyosin gene; TTN- cardiac titin gene; WPW- Wolff-Parkinson-White 
syndrome. 
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1.5.3 Phenotypic variability of HCM 
The phenotypic expression of HCM varies not only with mutations in different genes, but 
with different mutations in the same gene. This has been noted particularly with mutations in 
MYH7, TNNT2 and MYBPC3. For example, the majority of missense mutations identified in 
MYH7 (Arg403Trp, Phe513Cys, Leu908Val and Gly256Glu) are associated with benign 
clinical and near-normal expectancy, but there are those (Arg403Gln, Arg453Cys and 
Arg719Trp) that cause a severe form of HCM with early onset that is accompanied by a high 
risk of outflow obstruction and sudden death (Watkins et al., 1992; Anan and Greve, 1994). 
The benign nature of the Arg403Trp mutation was also noted in a large South African kindred 
(Posen et al., 1995).  
 
Mutations in MYBPC3 are also associated with a broad spectrum of HCM phenotypes 
(Erdmann et al., 2001). For example, the most severe manifestations of the disease, including 
life-threatening arrhythmias, have been noted in affected individuals with protein truncations. 
In contrast, affected individuals with missense mutations generally exhibit a mild form of 
HCM with late onset of symptoms and a favorable prognosis before the age of 40 years 
(Charron et al., 1998; Niimura et al., 1998). 
 
The disease caused by TNNT2 mutations is usually associated with low penetrance, a 
relatively mild and sometimes subclinical hypertrophy, but a high incidence of sudden death 
in the absence of clinical left ventricular hypertrophy (Watkins et al., 1995; Moolman et al., 
1997; Nakajima-Taniguchi et al., 1997). However, a different phenotype has been reported in 
one family with a TNNT2-Phe110Glu missense mutation, which presented a more benign 
form of HCM phenotype with no sudden death, although the hypertrophy itself was overt 
(Anan et al., 1998; Watkins et al., 1995). Genetic studies have also revealed that, in some 
cases, a quarter of genetically affected individuals are clinically asymptomatic, although the 
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mutant allele is associated with a typical phenotype of the disease in first-degree relatives 
(Dausse et al., 1993; Carrier et al., 1997). The degree of functional impairment caused by a 
particular mutation in a sarcomeric component has been reported to account, in part, for the 
variability of the phenotypic expression of the mutations (Bonne et al., 1998). The functional 
impairement may vary with the position of the mutation in the molecule, the type of protein 
involved and modifying factors.  
 
1.5.4 Mechanisms underlying the pathogenesis of HCM 
Several mechanisms have been postulated by which HCM-causing mutations in genes 
encoding sarcomeric proteins may caused HCM. The mechanisms predicted were based on 
knowledge of the molecular structures of sarcomeric proteins in conjunction with biochemical 
and biophysical properties of muscle contraction (Seidman and Seidman, 2001). The 
mechanisms involve either inactivation of the normal allele by the dominant gene mutation, 
resulting in a reduced amount of the functional protein (haploinsufficiency), or the creation of 
a mutant protein that interferes with normal function of the protein (dominant negative effect). 
Most HCM-causing mutations are missense mutations or minor truncations that are unlikely 
to cause haploinsufficiency. Functional analyses of transcripts with missense mutations 
demonstrated that the mutant proteins are incorporated into cardiac myofilaments, supporting 
the “dominant negative effect” hypothesis (Watkins et al., 1996; Rust et al., 1999). Attempts 
have been made to explain this concept, but biochemical studies performed demonstrated 
conflicting results. 
 
Initial biochemical studies of Arg403Gln MYH7 mutation performed using muscle biopsy 
specimens from HCM-affected individuals demonstrated a reduced actin filament 
translocation and force generation when compared with control muscle (Lankford et al., 1995; 
Sata and Ikebe, 1996), whereas, others showed increased actin-activated ATPase activity, 
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force generation and actin filament sliding velocity (Tyska et al., 2000; Lowey, 2002). 
Furthermore, in vitro motility assays performed using embryonic rats carrying the TNNT2-
In15G>A substitution showed increased velocity of actin-tropomyosin filament translocation 
and decreased maximum force in the presence of Ca2+ (Lin et al., 1996; Sweeney et al., 1998; 
Homsher et al., 2000). In contrast, functional studies performed with transgenic animal 
models demonstrated increased Ca2+-sensitivity of force generation caused by TNNT2-
Arg92Gln and TNNT2-Ile79Asn mutations (Morimoto et al., 1998). In addition, functional 
studies performed on HCM-causing mutations in other sarcomeric protein-encoding genes 
(MYL3 and MYL2) showed increased Ca2+ sensitivity (hypercontractility) of force production, 
thereby increasing force at submaximal Ca2+ concentrations (Rayment et al., 1995; Fujita et 
al., 1997; Elliot et al., 2000; Michele et al., 1999). These findings suggest that contractile 
abnormalities caused by mutations in sarcomeric proteins may not be the unifying dysfunction 
in HCM, rather, alterations in molecular processes of muscle contractions activate signalling 
pathways, which trigger myocyte growth and ultimately cardiac hypertrophy (Seidman and 
Seidman, 2001; Ashrafian et al., 2003). Two mechanisms have been proposed that are 
unifying dysfunctions in HCM, namely, calcium dysregulation and energy depletion 
(Seidman and Seidman, 2001; Ashrafian et al., 2003). 
 
Calcium dysregulation 
The release of Ca2+  from intracellular stores plays a key role in a wide variety of biological 
functions such as excitation-contraction, excitation-secretion coupling, as well as transcription 
and apoptosis (Buratti et al., 1995). Calcium regulates muscle contraction by binding to TnC, 
after it is released from the SR, causing a conformational change that weakens the interaction 
between TnI and actin-αTm, and strengthens TnI-TnC interaction (Solaro and van Eyk, 1996; 
Bers, 2000) (section 1.1.4).  
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The role of calcium dysregulation in HCM was demonstrated in studies of nongenetic causes 
of HCM, which indicated that angiotensin II mediates growth of cultured myocytes by 
altering Ca2+ concentration (Ito et al., 1997). Increased Ca2+ has also been noted in rats with 
surgically induced pressure-overload hypertrophy (Zolk et al., 1998). Additional evidence has 
been noted in functional studies performed with transgenic mice harbouring the Arg403Gln 
MYH7 mutation, in which both normal and mutant-containing myocytes were treated with 
cyclosporin, a calcineurin inhibitor (Fatkin et al., 2000). Calcineurin is a cytoplasmic protein 
phosphatase that is activated by sustained increase in intracellular Ca2+ (Crabtree, 1999). 
Activated calcineurin dephosphorylates a nuclear factor of activated T cell (NFAT3) 
transcription factors that causes their translocation to the nucleus where they bind to the zinc 
finger transcription factor GATA4, leading to activation of embryonic cardiac genes and a 
hypertrophic response (Crabtree, 2001). In transgenic mouse models, calcineurin inhibition in 
normal myocytes resulted in increased resting intracellular Ca2+ concentration. In contrast, 
myocytes expressing the myosin mutant fail to elevate intracellular Ca2+ in response to 
calcineurin inhibition, although the development of hypertrophy was accelerated and severe 
(Fatkin et al., 2000). These data indicate that abnormal Ca2+ regulation may play an important 
role in hypertrophic response in HCM. 
 
Energy depletion 
The PRKAG2 was the first nonsarcomeric protein-encoding gene to be implicated in causing 
HCM (Arad et al., 2001; Gollob et al., 2001), suggesting that sarcomeric dysfunction is not 
the fundamental defect in HCM. The PRKAG2 mutations that cause HCM raised the 
possibility that abnormal myocardial energy regulation may be another common mechanism 
by which HCM mutations result in the development of the disease. The γ2 subunit of AMPK 
has been reported to have a sensing mechanism for protecting cells from ATP depletion by 
regulating diverse intracellular pathways that utilise and generate ATP (Blair et al., 2001). It 
  
38
is activated by cellular stresses that reduce ATP levels and increase AMP, with AMP acting 
as the main activator interacting with both the autoinhibitory region in the α subunit and the 
γ−subunit. Upon activation, AMPK switches on catabolic pathways by phosphorylating 
metabolic enzymes and reducing the activity of non-essential ATP-consuming processes, 
restoring the energy balance.  
 
The “energy depletion” hypothesis is supported by findings obtained in one study, in which 
the mean phosphocreatine (PCr)/ATP and Pi/PCr ratios were determined in HCM-affected 
individuals using P NMR spectroscopy (Jung et al., 1998). The study demonstrated a 
significantly decreased PCr/ATP ratio and significantly increased Pi/PCr, indicating an 
abnormal phosphate metabolism. Possible causes of the abnormal phosphate metabolism have 
been suggested: accelerated work of the heart under resting whole-body conditions, oxygen 
limitation to cell metabolism severe enough to invoke significant anaerobic contribution to 
ATP turnover rates and altered carbon and energy sources fueling the cardiac tissue. A 
transgenic Arg403Gln α-MHC gene (MYH6) mouse model also demonstrated similar 
depletion of PCr/ATP ratios (Spindler et al., 1998). Furthermore, increased lipid deposition 
and mitochondrial pathology was noted in mouse cardiac tissue expressing high levels (92 %) 
of the TNNT2-Arg92Gln mutant, although the sarcomeric structure was not altered (Tardiff et 
al., 1999). This phenotype strongly suggested that total cellular metabolism (usage of cellular 
ATP) was altered.  
 
Thus, in their hypothesis, Ashrafian and coworkers (2003) linked Ca2+ dyregulation and 
energy depletion by proposing that energy depletion is the primary stimulus of hypertrophy in 
HCM, with Ca2+ acting as a sensor for cellular energy balance. If there is an imbalance 
between energy generation and consumption, energy requiring processes such as the 
SERCA2a pump will be compromised resulting in improper Ca2+ re-uptake/removal at the 
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end of each contractile cycle. Consequently, prolonged cytosolic Ca2+ will result to activation 
of downstream signalling elements such as calcineurin, members of NFAT3 transcription 
factor, Ca2+/calmodulin-dependent protein kinase and p38 mitogen-activated protein kinase, 
and ultimately to hypertrophy. 
 
1.5.5 Gene expression profile in both DCM and HCM 
Multiple changes in gene expression have been found to occur in response to heart failure, 
and DCM and HCM are known to be the leading cause of heart failure worldwide (Lim et al., 
2001; Hwang et al., 2002). During the development of heart failure, cardiac myocytes 
undergo structural and functional changes, that initially, are compensatory but later become 
deleterious. In an attempt to uncover the mechanisms underlying cellular remodelling as a 
result of DCM, gene expression profiling was performed in cardiac biopsies of DCM-affected 
individuals (Yang et al., 2000; Grzeskowiak et al., 2003). RNA microarray analyses 
demonstrated overexpression or downregulation of a large number of genes, which is thought 
to be a secondary response to heart failure. Genes with altered expression profile were 
categorised into several groups, namely, cytoskeletal and sarcomeric genes, genes involved in 
cellular energetics, stress protein-encoding genes, genes responsible for protein synthesis and 
genes responsible for myocardial protein degradation and disassembly (Yang et al., 2000; 
Grzeskowiak et al., 2003). Alterations in expression profile of the same group of genes was 
also noted in cardiac specimens obtained from HCM-affected individuals, although the 
numbers of transcripts differed in each case. For example, more transcripts that belong to the 
metabolism subcategory were downregulated in DCM samples than in HCM samples. These 
studies suggest that the expression level and the number of genes downregulated or 
upregulated reflect the biological significance of different genes in both HCM and DCM 
(Hwang et al., 2002). 
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1.6. Genetic modulating factors of the HCM phenotype 
One of the characteristics of HCM is the presence of variability in its phenotypic expression, 
particularly the extent of hypertrophy and sudden cardiac death (Klues et al., 1995; Moolman 
et al., 1997; Maron et al., 2000). The phenotypic variability is caused, in part, by the genetic 
heterogeneity and the diversity in causal mutations as highlighted in section 1.5.2. The 
heterogeneity in the HCM phenotype reflects underlying differences in biophysical properties 
of mutant proteins, however, it is most likely that other factors, genetic background and/or 
environmental factors, may also influence the disease expression. This became evident when 
identical mutations identified in different populations were observed to cause distinct 
hypertrophic morphologies and variable clinical outcome (Watkins et al., 1992; Fananapazir 
and Epstein, 1994). For example, the MYH7-Arg403Gln mutation that was generally 
associated with a malignant HCM was reported to have a benign outcome in one Korean 
family, in which none of the six mutation carriers died at the time of the study (Fananapazir 
and Epstein, 1994). Similarly, the MYH7-Val606Met benign mutation manifested with severe 
hypertrophy and high incidence of sudden death in four of the eight HCM-affected individuals 
of one family (Watkins et al., 1992; Fananapazir and Epstein, 1994). Furthermore, phenotypic 
variability has also been observed among affected individuals of the same family who carry 
identical mutations. For example, in one family study conducted by Kimura and co-workers 
(1997), a TNNI3 Lys183del mutation was identified in a family member who had apical 
HCM, while another family member with the same mutation had a classical HCM. This 
mutation has also been reported in other seven families in which only one affected individual 
presented with apical HCM (Kokado et al., 2000). 
 
The influence of genetic background on HCM phenotypic expression has also been 
investigated and reported in monozygotic and dizygotic twin studies, where a variability in 
cardiac size was noted irrespective of other factors (Adams et al., 1995). This corresponds 
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with the findings from a family study in which siblings of individuals with LVH were 
reported to have a higher risk of developing LVH according to the echocardiographic 
measurements and statistical analyses (Schunkert et al., 1999). The contribution of genetic 
background to HCM phenotypic expression has also been demonstrated in transgenic animal 
models (Semsarian et al., 2001; Sebkhi et al., 1999). In one study performed with two inbred 
normotensive rat strains, a quantitative trait locus (on chromosome 3) was identified by 
linkage analysis that affects the difference in cardiac mass of these two strains (Sebkhi et al., 
1999). In another study conducted in   α-MHC403/+ knockout inbred and outbred mouse 
models, variability in cardiac hypertrophy was observed which was believed to be influenced 
by genetic factors irrespective of body weight and exercise (Semsarian et al., 2001). These 
studies support the hypothesis that genetic modifiers can influence the response to 
mutationally altered sarcomere proteins in humans. 
 
Studies performed with different human populations have implicated several genes as 
candidate modifiers for hypertrophy in HCM, for example, genes encoding components of the 
renin-angiotensin system, endothelin and its receptors, tumor necrosis factor (TNF-α), 
chymase, bradykinin and its receptor, aldosterone synthase, insulin-like growth factor-2 (IGF-
2), transforming growth factor-β1 (TGFβ1), interleukin 6 (IL6), and platelet activating factor 
acetylhydrolase (Patel et al., 2000; Osterop et al., 1998; Deinum et al., 2001; Marian et al., 
1993; Lechin et al., 1995; Yoneya et al., 1995; Pfeufer et al, 1996; Tesson et al., 1997; 
Yamada et al., 1997). However, analyses of polymorphisms within these genes have shown 
conflicting results and only explain a small portion of the observed phenotypic variability in 
HCM. In a study conducted on a Caucasian group of genetically independent HCM-affected 
individuals, potential modifier genes were investigated for their role in the variability of 
cardiac hypertrophy (Patel et al., 2000). The TNF-α -308G/A variant was associated with the 
expression of left ventricular hypertrophy (LVH). The AA genotype was associated with 
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increased LVH when compared with other genotypes. However, functional variants of other 
candidate modifier genes (TGFβ1, aldosterone synthase gene, IL6 and IGF-2) that were 
previously implicated to play a role in cardiac hypertrophy (Yokoyama et al., 1997; Hirota et 
al., 1995; Brand and Schneider, 1995; Nezer et al., 1999; Jeon et al., 1999) were not 
associated with variable expression of the LVH. 
 
The most commonly studied of these potential modifier genes, ACE, that encodes the 
angiotensin-1 converting enzyme-1 (ACE-1), has given the best supportive evidence of a role 
in modulating HCM compared to others. An insertion/deletion (I/D) polymorphism was 
identified in ACE that was found to be associated with the risk of sudden cardiac death in 
HCM-affected individuals, with the DD genotype more common in HCM families with a high 
incidence of SCD compared to those with a low incidence of SCD (Marian et al., 1993). 
Subsequent studies have supported this finding by demonstrating an association between the 
I/D genotype and the severity of HCM (Lechin et al., 1995; Tesson et al., 1997). In one study, 
the association of the I/D genotype was reported to be dependent not only on the particular 
sarcomeric main locus gene but, also on the causal mutation, and a significant association was 
observed in HCM-affected individuals with the MYH7-Arg403Gln mutation but not in 
affected individuals with a splice acceptor site mutation in MYBPC3. This implies that the 
trigger for hypertrophy development in response to sarcomeric functional impairment may be 
influenced by several modifying genes (Tesson et al., 1997). 
 
1.7. The present study: Aim and design 
The aim of the study was to: i) identify PFHBII candidate genes and to screen prioritised ones 
for the causative mutation, ii) to screen the PFHBII plausible candidate genes for HCM main 
locus mutations and/or variants that may modify hypertrophy in HCM. As a strategy to identify 
PFHBII-causative genes within the PFHBII locus, a catalogue of genes previously reported as 
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cause of DCM (pure and DCM associated with cardiac conduction system disorder), HCM and 
conduction system disease was created. Genes in the catalogue were used as a reference to 
search for genes with homologous functional domains within the PFHBII locus using BLAST 
similarity search. This is based on the fact that DCM is the primary feature of PFHBII, and 
DCM-causing mutations were also identified in genes (MYH7, TNNT2, ACTC and TPM1) in 
which other mutations were shown to cause HCM. Furthermore, HCM-affected individuals 
have been reported to develop a DCM-like phenotype at a later stage, although it is still unclear 
whether this is an end-stage HCM phenotype or a transition from HCM to DCM (Seidman and 
Seidman, 2001). This is noted in affected individuals harboring TPM1-Glu180Val, MYH7-
Arg453Cys, MYH7-Leu517Met, MYH7-Gln734Glu and MYBPC3-Gln1012X mutations. This 
has caused a fundamental paradigm shift with regard to exclusive causes of HCM and DCM 
(Olson et al., 2001; Moolman-Smook et al., 2003). Furthermore, HCM and DCM with 
associated conduction system defects are commonly noted in conjunction with each other. 
These data may indicate common pathophysiological events leading to conduction disorders, 
HCM or DCM, and may provide a handle to identify the cause of PFHBII. Therefore, any gene 
within the PFHBII locus that is structurally and/or functionally related to genes implicated as 
causing DCM or HCM, is a plausible candidate for PFHBII mutation analysis.  
 
Apart from using BLAST similarity search to identify plausible PFHBII candidates, Ensembl 
and UCSC gene identification tools were also used. Genes were considered strong candidate 
genes if they lie within the PFHBII locus, are expressed in the cardiac tissue, and play a 
structural and/or functional role in the heart. The plausible candidate genes were screened for 
the possible PFHBII-causing mutation in the PFHBII family using polymerase chain reaction-
based single strand conformation polymorphism (PCR-SSCP) mutation analysis and automated 
sequencing. In addition, plausible PFHBII candidate genes were screened for HCM main locus 
mutations and/or variants that may either modify the expression of the HCM phenotype or 
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contribute to the development of the disease. Allele specific restriction enzyme analysis was 
used to confirm the presence of identified variants and to genotype other individuals in the 
families of HCM proband. Thereafter, the association between the identified genotypes and the 
disease phenotype was determined by a quantitative transmission disequilibrium test (QTDT).  
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Figure II.13. Flow chart summarising the design of the present study. Explained in the text. 
Abbreviations: BLASTn/p- basic alignment search tool for nucleotides and protein sequences, PCR-
SSCP- polymerase chain reaction-based single strand conformation polymorphism analysis, ASREA- 
allele specific restriction enzyme analysis. 
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2.1 Identification of candidate genes within the PFHBII locus 
2.1.1 Preparing a catalogue of cardiac conduction system disease-, DCM-, and HCM-
causing genes 
Database searches (appendix I) and previously published material were used to prepare a 
catalogue of genes that have been reported to cause CCS disease, DCM (pure or associated with 
CDDC), or HCM. The chromosomal locus and the accession number of each gene were also 
included in the catalogue.  
 
2.1.2 Basic Alignment Search Tool (BLAST) search 
The discovery of DNA and amino acid sequence homology to a known gene and protein, or 
protein family, often provides the first clues about the function of a newly sequenced gene. 
There are a number of software tools for identifying sequence homology between two 
sequences and BLAST is one of them (appendix I). BLAST programs have been developed to 
compare protein or DNA queries with protein or DNA databases in any combination, with 
DNA sequences undergoing conceptual translation before any comparison is performed. The 
BLASTN and BLASTP option of the NCBI-BLAST programmme compares sequence queries 
to nucleotide (BLASTN) or protein databases (BLASTP) (Altschul et al., 1990). 
 
The two BLAST programs, BLASTN and BLASTP (appendix I), were used in the present 
study to search for genes within the PFHBII locus with sequences homologous to those of the 
catalogued genes.  
 
Nucleotide BLAST (BLASTN) search  
The BLAST search was initiated in June 2001, at the time, the sequence status of the human 
genome was in a draft form and gene annotation was incomplete (refer to section 1.2). The draft 
genome sequence consisted of approximately 25,790 genes (release 0.8.0), including 94% of 
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known genes, out of 30,000-35,000 genes that were predicted using expressed sequence tags 
(ESTs), comparative genomics and the completed human chromosomes (Semple et al., 2001). 
Thus, complete in silico or electronic versions of coding nucleotide sequences of several genes 
were available in the NCBI, Ensembl and UCSC databases. Coding sequences of the 
catalogued genes were obtained (using the “copy” option) from GENBANK (NCBI website) 
and entered (using the “paste“ option) in a FASTA format into the “query” window at the 
NCBI BLAST or Ensembl BLAST (appendix I) webpage. The “masking” option (also known 
as the low complexity filter option) was chosen to minimise the influence of the low 
complexity regions. This option was selected because many regions throughout eukaryotic 
genomes consist of sequences that code for transmembrane helices or coiled-coil domains, 
which may, therefore, result in false-positive alignments (Huynen et al., 1998). The query 
sequence was then submitted and the results were accessed in a separate web page. A 
significant threshold level of 95% or greater, or e-value less that 0.01, was used to select 
sequences homologous to a “query” sequence of 40 nucleotides or more (Altshul et al., 1997; 
NCBI BLAST tutorial). The algorithm indicates the difference between alignment matches that 
have only mathematical significance and matches that have a biological significance (Altshul et 
al., 1997) 
 
Protein BLAST (BLASTP) search  
BLASTP can be used to find homologous protein coding regions by directly entering the 
sequence of the protein encoded by the gene to be analysed into the query window. Protein 
sequences of genes in the catalogue were submitted to BLASTP, as described in the above 
section. All resultant sequence alignments with an e-value lower than 0.01, or with percentage 
identity of 40-50%, were considered significant (Altschul et al., 1997). 
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Initially, the present study searched for functional domains in the PFHBII locus that were 
homologous to functional domains of proteins in which mutations have been described as 
causing DCM associated with CCS disorders. CCS disorders complicated with arrhythmia and 
HCM were also included in the search for the reasons discussed in section 1.7. However, as the 
study progressed, improvements were made to bioinformatics search tools, which resulted in 
the use of a modified bioinformatics approach to identify possible PFHBII and HCM candidate 
genes at the PFHBII locus, as described in the following subsection. 
 
2.1.3 Databases used to identify annotated genes within the PFHBII locus 
Newly annotated genes were continuously added to the PFHBII locus as the human genome 
sequencing progressed. The Ensembl and UCSC databases (appendix I) provide tools for 
viewing annotated genes within specified genomic regions, their nucleotide and protein 
sequences, tissue expression profiles and their predicted functions. This information can be 
accessed in specific databases that are linked to the Ensembl and UCSC websites (appendix 
I). Therefore, in addition to using the BLAST search of different databases and comparing the 
results, Ensembl and UCSC gene identification tools were also used. 
 
Ensembl gene identification tools  
The Ensembl home page provides links to genomic data of Homo (H) sapiens, Pan 
troglodytes, Mus musculus, Rattus (R) norvegicus, Danio rerio, Fugu rubripes, Anopheles 
gambiae, Drosophila melanogaster, Caenorhabditis elegans, Caenorhabditis briggsae, and 
Gallus gallus. The PFHBII locus was viewed in the contigview web page by clicking 
chromosome 1 (see website) and selecting the region flanked by markers D1S70 and D1S505. 
The contigview web page allows the user to scroll along the entire chromosome, and, it allows 
the user to click on an annotated (in silico) transcript (known or computer predicted), which 
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activates links to other databases that have more detailed information about the gene in 
question. (Fig 2.1).  
 
 
Figure 2.1 A representation of Ensembl contigview showing a region in human chromosome 1. The 
region is shown at high resolutions and detailed information on each annotated gene can be accessed 
by clicking in any of them. Genes are coloured brown. Novel ‘Ensembl genes’ are shown in black. 
Taken from Ensembl database (appendix I). 
 
 
UCSC gene identification tools 
Alternatively, the PFHBII region was accessed via the UCSC browser. In this case, a search 
for a gene was performed by specifying the chromosomal region, which can be viewed either 
as a chromosome band or a range of bases (e.g. chr 1: 206860725-209674431bp). GENSCAN 
gene predictions (known and novel genes), mRNA alignments or interspersed repeats are 
graphically displayed in the middle of the UCSC web page (Fig. 2.2). Clicking on a transcript 
accesses information relevant to that particular gene, as all information in the UCSC database 
is linked to other websites (e.g., GO, GENSCAN). Thus, candidate genes could be selected 
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using the comprehensive data provided in the UCSC database, as well as information obtained 
in other specialised databases. 
 
For the present study, it was opted to use the Ensembl and UCSC databases to identify 
plausible candidate genes at the PFHBII locus. Data obtained from both databases were 
compared to each other, thereby creating a comprehensive profile of the selected candidate 
gene. New candidate genes were prioritised according to their tissue expression profile and 
their possible role in cardiac functioning. Genes selected within the PFHBII locus were 
screened for PFHBII-causative mutation, as well as for HCM main locus and/or HCM-
modifying mutations (as discussed in chapter 1). 
 
 
Figure 2.2 A representation of the UCSC main browser display showing a region of human 
chromosome 1. The web page contains three main panels: The top panel contains a series of 
controls that are used for searching, zooming and scrolling across a chromosome. In the 
middle panel is a graphic display of annotated genes at a locus. Detailed information on the 
selected gene can be accessed by clicking in any of the genes (see text). Taken from UCSC 
database (appendix I). 
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2.2 Identification of promoter elements of candidate genes 
Gene expression profiling has been performed in DCM and HCM-affected individuals and 
several genes have been reported to have altered expression levels, which may be due to 
mutations in promoter elements (Yang et al., 2000; Grzeskowiak et al., 2003) (section 
1.4.3.3). For this reason, promoter regions of candidate genes were also screened for possible 
mutations that may affect the expression level of these genes in affected individuals. 
 
2.2.1 PFKFB2 promoter region 
The promoter region of PFKFB2 is not completely characterised and in order to analyse this 
region for PFHBII- and HCM-causing and/or modifying mutations, and to predict the effect 
of mutations in PFHBII and HCM, it was necessary to identify the promoter elements 
(transcription-binding sites) within this region. Five transcription-binding sites were 
previously identified within a 500-bp 5’ region of H. sapiens PFKFB2 which corresponds to 
exon 1 of the gene (Heine-Suner et al., 1998). In order to identify the exact positions of these 
five transcription-binding sites, European Bioinformatics Institute (EBI) alignment tools 
(appendix I) were used, and positions of three Sp1 sites and one HNF1 conserved 
transcription-binding sites were identified (refer to section 3.2.3).  
 
2.2.2 ATF3 promoter region 
The ATF3 promoter region is well defined and is available in NCBI nucleotide database under 
the accession number U37542. 
 
2.3 Selection of subjects 
Mutation analyses were performed in two groups of subjects, namely, the PFHBII-affected 
family (Brink and Torrington, 1977; Fernandez et al., 2004) in which candidate genes were 
analysed for PFHBII-causing mutations, and the HCM panel (Moolman-Smook et al., 2000), in 
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which candidate genes were analysed for HCM main locus and/or modifying mutations. The 
selection of subjects making up the two groups is described below.  
 
2.3.1 PFHBII family 
The study was approved by the Ethics committee of the University of Stellenbosch, Tygerberg, 
and informed vocal and written consent (parental consent in the case of minors) was obtained 
from all individuals entered into the study. PFHBII has been described in one family only (Fig 
2.3) (Brink and Torrington, 1977). Clinical records and family history of 24 members of the 
PFHBII family were previously collected and filed for a long-term study. These individuals 
were examined and described in the original PFHBII study (Brink and Torrington, 1977), and 
have been followed to the present and the clinical data was collected as part of an ongoing 
study (Fernandez et al., 2004). Affected and unaffected individuals that were entered into this 
author’s study are shown in table 2.1. 
 
2.3.2 HCM panel 
The study was approved by the Ethics committee of the University of Stellenbosch and 
informed vocal and written consent (parental consent in the case of minors) was obtained from 
all individuals entered into the study. The HCM panel was established from South African 
HCM-affected individuals and individuals with echocardiographic HCM-like features, and 
forms part of an ongoing study conducted by Dr. Moolman-Smook in the Department of 
Medical Biochemistry, Faculty of Health Sciences (University of Stellenbosch). The panel 
consisted of 143 unrelated individuals of different ethnic backgrounds (Coloured, Blacks and 
Caucasians), 31 with previously identified HCM-causative mutations (MYH7-Ala797Thr, 
MYH7-Arg249Gln, MYH7-Arg403Trp, MYH7-Glu499Lys, MYH7-Arg719Trp, MYH7-
Ala1379Thr, MyBPC3-∆c756, MyBPC3-Arg654His, MyBPC3-Val896Met, MyBPC3-
IVS7+1G>A, TNNT2-Arg92Trp, and TNNTI3-Arg186Trp) (Fung et al., 1999; Moolman et al., 
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1993; Moolman et al., 1995; Moolman-Smook et al., 1998; Moolman-Smook et al., 1999; 
Moolman-Smook et al., 2000). The panel was screened continuously to identify new causative 
mutations as the previously identified mutations only account for approximately 22% of the 
total (Dr. Moolman-Smook, personal communication), and were not found in other affected 
individuals in the panel. 
 
Clinical information about affected individuals was obtained from Tygerberg Hospital (Cape 
Town, RSA), clinics, private practises and other hospitals nationwide through collaboration 
between the University of Stellenbosch and physicians. Family trees, or a preliminary pedigree 
structure of individuals entered into the study, were traced by Sr Althea Goosen, if the family 
had a history of the FHC. In addition, a detailed history and clinical records of the probands and 
their relatives, where possible, were also obtained by Sr Goosen to establish the frequency of 
sudden deaths and disease-related deaths. Probands with clinical features and a history of 
HCM, or any individuals who demonstrated HCM-like hypertrophy and symptoms upon 
examination, were continuously identified, informed of the HCM mutation screening project, 
and given the opportunity to participate if they so wished. 
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Figure 2.3 A four-generation pedigree of the PFHBII-affected family. The roman figures represent 
the four generations of the family, squares indicate males; circles indicate females. Open symbols 
indicate individuals of unknown clinical status; N indicates unaffected individuals; solid symbols 
indicate PFHBII-affected subjects; diagonal lines indicate deceased individuals; question marks 
indicate individuals of unknown clinical status; arrow shows the proband. The numbers represent 
identification numbers of family members and those that were analysed (both affected and unaffected) 
are indicated by asterisks. Adapted from Fernandez et al., 2004. 
**
** *
* *
*
*
* *
* *
II
III
IV
*
I
  
57
Table 2.1 Follow-up clinical data of PFHBII-family members that were clinically assessed in 
the original study (Brink and Torrington, 1977) and screened for the PFHBII-causing 
mutation in the present study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b = heart rate prior to pacemaker (PM) implant; c = individuals with atypical accompanying features 
+ = age at death; 1° = first-degree; AF- atrial fibrillation; AVB = atrioventricular block; bpm = 
beats per minute; CHB = complete heart block; DCM = dilated cardiomyopathy; m/s = 
milliseconds; (PM _y) = PM age at implant; SB = sinus bradycardia, y= years (data modified 
from Fernandez et al., 2004). 
 
 
 
 
 
 
Individual Age (y) at 
diagnosis 
Comments 
1554 68 unaffected 
1088 42 bSB = 48 bpm, CHB (PM 42y); present age = 69y 
(affected) 
1556 64 unaffected  
909 37 CHB (PM 37y), DCM, +59yrs (affcted) 
1680 49 unaffected  
1751 45 unaffected 
1351 33 1° AVB (P-R interval = 220 m/s, March 1990), cSB = 
38 bpm, AF, CHB (PM 33y, October 1996); present 
age = 38y (affected) 
1353 45 unaffected  
1791 41 CHB (PM 41y), DCM, +46y (affected) 
1928 38 1° AVB (P-R interval = 240m/s, May 2000); SB = 43 
bpm, Wenckebach/complete AVB (PM 38y), January 
2003; present age = 38y (affected) 
1553 41 unaffected 
908 39 unaffected 
1752 29 CHB (PM 29y), DCM, +43y (affected) 
1106 23 chest pain, dyspnoea, syncope (atypical) 
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2.4 Mutation analysis by polymerase chain reaction-single strand conformation 
polymorphism (PCR-SSCP) method 
2.4.1 Principle 
Single-strand conformation polymorphism is a PCR-based mutation detection technique (PCR-
SSCP) that detects sequence changes, including single-base substitutions, as differences in 
electrophoretic mobility (Orita et al., 1989). The PCR-SSCP analysis is based on the principle 
that the primary structure of a single-stranded DNA molecule changes under mildly denaturing 
conditions, to a specific sequence-based secondary structure. The secondary structure is due to 
base pairing between nucleotides within each strand and depends on the length of the strand, 
the location and number of regions of base pairing, and the primary sequence of the strand. 
Single-stranded DNA molecules that differ by at least one nucleotide will assume different 
conformations, and hence, have different electrophoretic mobilities when run in non-denaturing 
polyacrylamide gels. 
 
PCR-SSCP has been used to detect mutations and polymorphisms in small amplicons (100-
300bp) and provides a useful and cost effective alternative for the direct detection of genetic 
variation, particularly when large numbers of samples are required for analysis (Cotton, 1997; 
Gasser, 1997). 
 
2.4.2 Polymerase chain reaction (PCR) 
Target regions of candidate genes to be analysed by PCR-SSCP were amplified using PCR, a 
technique used for rapidly amplifying DNA sequence exponentially by extending two short 
sequences (primers) that are annealed or hybridised to a unique region flanking the target DNA 
sequence (Saiki et al., 1985).  
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2.4.2.1 Primer design 
Oligonucleotide primers that were used for amplifying the coding and promoter regions of two 
candidate genes, PFKFB2 and ATF3, were designed from genomic sequences of these genes 
using DNAMAN (Lynnon Biosoft Copyright) and Primer Premier (Premier Biosoft 
International) computer programs. The genomic sequences of PFKFB2 and ATF3 are available 
in the NCBI nucleotide database under the following accession numbers: PFKFB2- AJ005577 
or AJ005578, ATF3- L19871. Melting temperatures (tables 2.2-2.5) and the GC content of the 
primers were also determined using the above primer-designing programs. Primers for 
amplifying exons of candidate genes were designed in such a way that portions of introns 
preceding and following the exons of interest were included (Fig. 2.4), which allowed 
investigation of the intron/exon boundaries (splice sites). These target sequences will be 
referred to as “coding regions” or “exons” in the text. Mutations in the splice sites can affect 
pre-RNA splicing, the size of the gene product and possibly its function, as they result in 
activation of cryptic splice sites, exon skipping, creation of a pseudo-exon within an intron, or 
intron retention (Watkins et al., 1995). For amplifying larger exons (exons greater than 310 bp), 
two overlapping pairs of primers were designed because of the limited DNA fragment size that 
is suitable for detection of sequence variations on SSCP analysis (Sheffield et al., 1993). The 
primer sequences were synthesised according to the standard phosphoramide method at the 
Department of Biochemistry, University of Cape Town (UCT, Cape Town, South Africa), and 
their sequences are shown in tables 2.2-2.5. 
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5’gactctagtcatttcgttttattttgagagaggagggagCATGGGCCTCCTACATGACCAACTCCCCGACTCTG
ATCGTTATGATTGGTTTGCCAGCCCGGGGTAAAACCTACGTGTCCAAGAAACTAACACGCTACCTCAACTGGATTG
GAGTCCCCACCAAAgtttattttgtccgagtaagggatcctttgt 3’ 
                       3’ggctcattccctaggaaaca 5’  
 
 
Figure 2.4 Nucleotide sequence of PFKFB2 intron 2-exon 3-intron 3. Intron sequences in lower case 
and exon in upper case. The forward and reverse primers that were used for amplifying exon 3 are 
shown in colour, and intron/exon boundaries are also indicated. 
 
2.4.2.2 PCR conditions 
DNA was amplified in a 50μl-reaction mixture containing approximately 100ng genomic DNA 
as a template, 75μM of each dATP, dTTP, dCTP and dGTP (Promega Corp., Madison 
Wisconsin USA), 5μl of a 10x Taq DNA polymerase buffer (Bioline UK Ltd, London, UK), 
120ng of each oligonucleotide primer, 0.5U Taq DNA polymerase (Bioline UK Ltd, London, 
UK), 1.5mM MgCl2, 5% formamide (Sigma Chemical Company, St. Louis, Missouri, USA) or 
5% dimethylsulfoxide (DMSO) (Sigma Chemical Company, St. Louis, Missouri, USA), the 
latter two components being used to reduce non-specific amplification, and H20 to a final 
volume of 50μl. Mineral oil was added to each tube to prevent evaporation during thermal 
cycling. The cycling parameters were as follows: denaturing the double stranded DNA at 94ºC 
for 30 seconds, annealing each primer to each single DNA strand at a specific temperature 
(tables 2.2-2.5) for 30 seconds, and extension of the primers by Taq DNA polymerase in the 
presence of dNTPs at 72ºC for 30 seconds. Amplification was performed in a thermal cycler 
(Gene E, Techne Ltd., Cambridge, England) and 30 cycles were done for each fragment of 
DNA amplified. 
 
Intron/exon boundary forward primer 
sequence 
Intron/exon  
boundary reverse primer sequence 
exon
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Table 2.2 Oligonucleotide primers used for amplifying PFKFB2 coding exons, their 
annealing temperatures, and size of generated fragments. 
Exon Primer sequence (5’-3’) Annealing 
temperature 
(oC) 
Product size 
(base pairs) 
3 F-GACTCTAGTCATTTCGTTTTATTTTG 
R-TCTTTCCTAGGGAATGAGCC 
48 196 
4 F-GCTGCTGAAGGATTTGGGTG 
R-GAAAGAGCTGACCTGGAGATC 
50 168 
5 F-CCTTGCTGGTTTCATTTGCTC 
R-GACCAGAAAGAAGAAGCAGCAGA 
50 130 
6 F-TGCTCATTTACCTTGTGTACTTTC 
R-CTCATCCCTTTTCCTCCAACAT 
50 144 
7 F-GCTTATCACTGCCTTCTCTC 
R-GGAGATGATATGTAGGGGT 
50 114 
8 F-GAGGCCTTTACTGGTTCCT 
R-GGCCCTTCAAACCATGGC 
50 185 
9 F-TCTCAGATCTTCTTACCTAGGG 
R-GCCTAGAAAATCCAGTGTGCT 
50 292 
10 F-GTGTTTTCTTTTTACCCTTAATTTTCAT 
R-TCTTGTTGGCTTTTCTGGGC 
50 230 
11 F-CTCTTCAAGCCAGCTTCAAGTG 
R-AAACACTCAGCAAGGGTCTAGGC 
50 190 
12 F-TGCCAGCCTGCCCCATTTCC 
R-TGTCTCCCAGCCCCTCCCTC 
50 186 
13 F-GACTTCCCTCGCCTGGTCTTT 
R-TCCTGCCAGCCCCTATGTG 
50 122 
14 F-TTAAGTCCTCTCTTTCCTCTG 
R-GGAAACTGGTGTGTTCATCG 
48 130 
*15 F1-GTGGAAGCTGTTGTGGT 
R1-CTGACTTGGGTCTTCGGCTA 
 
F2-CCGACTAGCCGAAGACCCAA 
R2-GCCCCTGGGTGAAAAGATGT 
50 
 
 
54 
285 
 
 
225 
*16 F1-ACTTCACCATTAATCTTAACACAG 
R1-TAGACTTTTTGTCCCCCGACT 
 
F2-AAGTGTTGGGGGATGGAGGG 
R2-TCTGGGCTGGCCCTTACAGG 
50 
 
57 
298 
 
320 
F- forward  primer, R- reverse primer. Asterick= overlapping primers were designed to amplify exons 15 and 
16. 
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Table 2.3 Oligonucleotide primers used for amplifying PFKFB2 promoter region, their 
annealing temperatures, and size of generated fragments. 
Promoter  Primer sequence (5’-3’) Annealing 
temperature 
(oC) 
Product size 
 (basepairs) 
Fragment 1 
 
Fragment 2 
 
PF1-AATGAGGTTCTGCTGGGAT 
PR1-GTGGCACTGTTGCTTGGTA 
PF2-GTTACCAAGCAACAGTGCCACC 
PR2-CCCTGTAACGCGACCGAA 
50 
 
56 
216 
 
276 
F- forward  primer, R- reverse primer 
 
Table 2.4 Oligonucleotide primers used for amplifying ATF3 coding exons, their 
annealing temperatures, and size of generated fragments. 
Exon Primer sequence (5’-3’) Annealing 
temperature (oC) 
Product size (base 
pairs) 
2a F-GGTGTTGGAGGTCTGGTG 
R-GATGGCAAACCTCAGCTCTTC 
54 238 
2b F-CACTGGTGTTTGAGGATTTTG 
R-GTGCCGAAAGAATGAATACCT 
51 193 
3 F-TTCTTACTGCCCTTTAAATGTG 
R-AGAGGAAGGGTAAGGCTAGAA 
52 181 
5 F-TGGCCCTTGGCTCCTTTCTT 
R-AGTCGCCCCCATACCACG 
57 266 
F- forward primer, R- reverse primer 
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Table 2.5 Oligonucleotide primers used for amplifying ATF3 promoter region, their 
annealing temperatures, and size of generated fragments. 
Promoter  Primer sequence (5’-3’) Annealing 
temperature (oC) 
Product size 
 (base pairs) 
Fragment 1 F-GTTCAACCTGTAAACTGGTCAAA 
R-GGGATTAGGTGGAGGAGTGT 
51 194 
Fragment 2 F-CTTCATTCAAATGCAAACACTCCT 
R-CGGGTGTTTTCGCTTTACTTTTC 
56 208 
Fragment 3 F-CAGGGCGAAAAGTAAAGCGAAAA 
R-TAGAGGTGTCTGGAGCCTGGGTC 
60 276 
Fragment 4 F-GTGTTTCTGCCCTTCACCGTGC 
R-AAACGATTTCCTGGTTCTTATTCC 
57 192 
Fragment 5 F-GGGTCGGGGAATAAGAACCAGGA 
R-GAAGAAGGTGCTTTGGGGTCCGC 
65 300 
Fragment 6 F-CCTCCCACCGGGTTGCCTCTGATT 
R-TGTGACCTCTGCGGCGGGGAC 
67 287 
Fragment 7 F-TAACGGAGTGGATACACCGAAGG 
R-GGCCCCAGCCCAGACTAGG 
60 206 
Fragment 8 F-CTCTTCAACCTAGCGGAGGGACA 
R-CCTCGCTCACTGAGACACACACC 
60 180 
Fragment 9 F-TGGGCTGGCTCCTCCCCGAACTTG 
R-CTGCGTGCGACTGTGGCTTGGAG 
70 237 
F- forward primer, R- reverse primer 
 
2.4.2.3 Agarose gel electrophoresis 
In order to assess the success of non-radioactive PCR amplification, agarose gels were prepared 
as follows: six to eight microlitres of each PCR product was mixed with 1-2μl of bromophenol 
blue loading dye (appendix II) and was subsequently electrophoresed in 2% horizontal agarose 
gel, containing 1μg/ml ethidium bromide and 1x TBE buffer (appendix II). The λPst molecular 
weight marker (appendix II) was co-electrophoresed with all PCR products, which were 
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visualised on a longwave transilluminator (3 UV transilluminator, California, USA). 
Electrophoresis of agarose gels typically occurred at 10V/cm for 20 minutes in 1x TBE running 
buffer, and the gels, thereafter, were visualised and photographed. 
 
2.4.3 PCR-SSCP method  
2.4.3.1 Gel casting 
The PCR-SSCP gels were used to detect mobility shifts in specific PCR-amplified exons of 
candidate genes. The gel was cast between two 390mm x 290mm glass plates, that were 
initially washed with Cal-liquid hand soap (Cal-Chem, R.S.A.), rinsed in tap water and dried 
with paper towel, and then further cleaned with 70% ethanol. The back plate was sprayed with 
70% ethanol in order to fix the GelbondTM PAG polyester film (FMC, Bioproducts, Rockland, 
Maine, USA) The hydrophilic side of the GelbondTM was exposed so that it would bind 
covalently with the gel solution (appendix I) when poured, thereby creating a solid support for 
the gel for subsequent silver staining. The front plate was silinised with Wynn’s C-THRU 
windshield rain dispersant (Wynn Oil S.A. Pty Ltd, SA). One-millilitre spacers were placed on 
either side of the GelBond-covered plate and the front plate was placed on top of the back plate 
with the silinised side on the inside. The sides of the plates and the bottom were sealed with 
gel-sealing tape (SIGMA, Germany) and then the casting rubber boot (S2 casting boot, LifeTM 
Technologies, UK) was fitted for further sealing. Two types of denaturing gel solutions, 8% 
acrylamide + 5% glycerol and 10% acrylamide + 5%glycerol (appendix II), were prepared and 
poured between plates making sure that there were no bubbles that would disrupt 
electrophoresis of the PCR products. The glass plates were then placed down horizontally, a 
square-tooth, well-forming comb fitted, the plates clamped and the gel allowed to set for 
approximately 1 hour. 
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2.4.3.2 Electrophoresis 
Once the gel was set, the casting boot, the sealing tape at the sides and at the bottom of the 
glass plates, and the comb were removed. The glass plate assembly was mounted vertically on 
the electrophoresis apparatus (Omeg Scientific, R.S.A), moved to the cold room (4˚C) and 0.5x 
TBE (appendix II) buffer added to the reservoir tanks. Before loading PCR amplified products, 
any residues inside the wells were removed by washing them with the electrophoresis buffer 
using a syringe. Five to eight microlitres of a 50μl PCR amplified product was mixed with an 
equal volume of SSCP loading dye (appendix II), and the samples were heat-denatured at 94˚C 
for 2 minutes and immediately loaded directly onto the non-denaturing gels. Control samples 
loaded onto the gels included a non-denatured sample as a control for electrophoretic migration 
of the double stranded DNA, a denatured PCR-amplified sample from an unaffected individual 
as a negative (wild type) control, and λPst as a molecular weight marker. Electrophoresis was 
carried out at a constant power of 50 watts (W) overnight at 4˚C until the dye front was three 
quarters of the length of the gel (depending on the product size of the amplified products). 
 
2.4.3.3 Silver staining 
Following electrophoresis of samples, the glass assembly was dismantled and the gel, still 
supported by the GelbondTM, was silver stained as follows: the gel was placed in a container 
with 50ml of solution B (0.1% AgNO3) (appendix II) and shaken gently for 10 minutes. 
Solution B was carefully discarded and the gel rinsed with water. Fifty millilitres of Solution C 
(appendix II) was then poured into the container to cover the gel, which was gently shaken until 
the bands were visible. The gel was then removed from the solution and hung to air-dry. 
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2.5 Sequencing 
Mobility shifts detected by PCR-SSCP analysis indicate the presence of sequence variations 
that cause different alleles to migrate differently in the SSCP gel. To confirm the presence of 
sequence variations, and to identify a particular variation, samples with different patterns were 
sequenced. Before sequencing, PCR products were purified to remove all other PCR reagents 
and other impurities that may interfere with the sequencing reaction and yield spurious results. 
 
2.5.1 Purification of PCR products for sequencing 
PCR-amplified products to be sequenced were purified using the GFXTM PCR DNA and Gel 
Band Purification kit (Amersham, Bioscience, UK) following the manufacturer’s instructions. 
The PCR-amplified products were loaded onto a 2% agarose gel, containing ethidium bromide, 
and electrophoresed together with the λPst molecular weight marker for approximately 1 hour 
in 1x TBE at room temperature. The PCR-amplified products were visualised on a longwave 
transilluminator and the correct size fragment, judged by the size of the molecular marker, was 
excised from the gel using a sterile scalpel blade. The gel was placed in a previously weighed 
1.5ml eppendorf microcentrifuge tube and again weighed in order to determine the correct 
volume of GFX capture buffer to mix with the gel. Ten microlitres of the GFX capture buffer 
was added for every 10mg of the gel slice, which were then mixed vigorously and incubated at 
60˚C for 10-15 minutes until the gel was completely dissolved. A GFX MicrospinTM column 
was placed in a 2ml capless collection tube and the dissolved gel was applied to the column and 
incubated at room temperature for 1 minute. The sample was then centrifuged in a Beckman 
microcentrifuge (Germany) at full speed for 30 seconds so that the DNA could bind to the 
column. The flowthrough was discarded and the column replaced into the same collection tube. 
A GFXTM wash buffer was added into the column, which was centrifuged at full speed for 30 
seconds. The collection tube was discarded and the GFXTM column was transferred to a fresh 
1.5ml microcentrifuge tube. A maximum of 50μl autoclaved double distilled H2O was added 
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directly to the top of the glass fibre matrix inside the GFXTM column. The sample was 
incubated at room temperature for 1 minute and centrifuged at full speed from 1 minute to 
recover the purified DNA. 
 
2.5.2 Automated sequencing 
The purified DNA fragments were sequenced using an ABI PrismTM 377 automated sequencer 
at the Department of Genetics (Central DNA Sequencer) at the University of Stellenbosch, 
Stellenbosch, South Africa. 
 
2.5.3 DNA sequence analysis 
Sequences obtained from ABI automated sequencing were compared to that of the GENBANK 
sequence, to ascertain sequence variations, using the NCBI pairwise2 blastn program and 
DNAMAN. Obtained sequences (reverse and forward sequences) were aligned using the NCBI 
pairwise2 BLAST program to remove ambiguous nucleotide bases and were subsequently 
aligned with the GENBANK sequence. The three sequences were then aligned using the 
Multiple Sequence alignment program in DNAMAN to identify any sequence variations and to 
determine their position in the gene. If there were any nucleotide changes identified, the 
sequence was then translated to determine the effect of the substitution on amino acid sequence. 
Mutation analysis was extended to a control population to determine whether the sequence 
variation was predicted to be disease-causing or a neutral polymorphism. In order to strengthen 
a functional role for the sequence variation, the analysis was extended to families (depending 
on the availability of DNA samples) of the individuals carrying the mutation or the 
polymorphism to investigate if it segregated with the disease phenotype.  
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2.6 Allele-specific restriction enzyme analysis 
2.6.1 Identification of restriction enzyme recognition sites within fragment 5 of the ATF3 
promoter region  
Allele-specific restriction enzyme analysis (ASREA) was performed to confirm the presence of 
sequence variations that were identified and to genotype other individuals in HCM families. 
This was performed by determining the effect of a particular sequence variation on a specific 
restriction enzyme recognition sequence. The sequence analysis program, DNAMAN, was used 
to generate a restriction enzyme map encompassing the relevant regions of both the 
GENBANK and variant sequences. This analysis was performed for all sequence variations that 
were identified, but only two of them (in fragment 5 of ATF3 promoter region) caused a gain or 
loss of the restriction enzyme recognition sequence. 
 
Three sequence variations were identified in ATF3 fragment 5 and two of them altered one 
restriction enzyme recognition sequence each. One polymorphism (-1068G/C) resulted in a loss 
of an NlaIII site (CATG/) while the other (-1229C/T) abolished the Alw26I site 
(GTCTCA(n)1/) that was identified in the region (Fig 2.5). 
 
2.6.2 Restriction enzyme digestion. 
The following procedure was performed on the ATF3 promoter region in which sequence 
variants were identified, but using different enzymes and appropriate 10x buffers for the 
different variants. Five microlitres of the relevant amplified PCR-product was aliquoted into a 
500μl-eppendorf microcentrifuge tube. Thereafter, 1.5μl of appropriate 10x restriction enzyme 
buffer (New England Biolabs), 1-2U of a restriction enzyme (NlaIII or Alw26I) and water to a 
final volume of 15μl were added to the PCR-product. The mixture was incubated at 37˚C for 2-
3 hours to allow digestion to proceed. Non-denaturing polyacrylamide gels (12%) were used 
for size separation of PCR-amplified products digested with restriction enzymes. 
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                        EcoRII         MseI             MnlI DdeI 
1      GGGGTCGGGGAATAAGAACCAGGAAATCGTTTTTAAGGTTCAAACCCAGTTCTGCTGAGG 
           Alw26I      AvaII   AsuI                  BglI           
       DdeI           AsuI    DraII               EcoRII   MnlI  BbvI 
61     TCTCAGCTCGAATCTCGGACCACGGGGCCCCGCCTTTCCCGCCACCCTGGCTTGAGGGCA 
                    Fnu4HI NlaIV HgaI                 EcoHI         
121    GAGGGGATTTCTGCTGCGGGTTCCGCCTGTGGTCAGTGCGTCCCCATTCCGGGCCGTCCG 
        NlaIV                      MaeII   AluI                     
181    GTCCCAGTCCAATCGGCTCTGGAGCGAGAGACGTGAAAGCTGAAGATGGTTTTCCCTAAA 
       Eco57I       BanI                    AccII     MboII         
241    TATGCCTGAGACGGCACCCCAGGCCTGGGCAGGTTCGCGGACCCCAAAGCACCTTCTTCT 
 
                        EcoRII         MseI             MnlI DdeI 
1      GGGGTCGGGGAATAAGAACCAGGAAATCGTTTTTAAGGTTCAAACCCAGTTCTGCTGAGG 
                       AvaII   AsuI                  BglI           
      DdeI            AsuI    DraII            EcoRII   MnlI  BbvI   
61     TCTTAGCTCGAATCTCGGACCACGGGGCCCCGCCTTTCCCGCCACCCTGGCTTGAGGGCA 
                    Fnu4HI NlaIV HgaI                 EcoHI         
121    GAGGGGATTTCTGCTGCGGGTTCCGCCTGTGGTCAGTGCGTCCCCATTCCGGGCCGTCCG 
        NlaIV                      MaeII   AluI     NlaIII    MboII 
181    GTCCCAGTCCAATCGGCTCTGGAGCGAGAGACGTGAAAGCTGAACATGGTTTTCCCTAAA 
       Eco57I      BanI                    AccII     MboII          
241    TATGCCTGAGACGGCACCCCAGGCCTGGGCAGGTTCGCGGACCCCAAAGCACCTTCTTCT 
 
 
Figure 2.5. Restriction enzyme map encompassing a 300 bp-ATF3 promoter region. a) GENBANK 
sequence, b) variant sequence. Resctriction enzyme recognition sites are printed in bold with the 
affected nucleotide written in blue.  
 
2.6.3 Gel casting and electrophoresis for detection of polymorphic restriction enzyme 
recognition sites 
A 12% polyacrylamide gel was prepared as described in appendix II. The gel was cast between 
two 100mm x 80mm-glass plates (wider plates were used if many samples were to be 
electrophoresed) that were pre-washed and cleaned with 70% ethanol. After the gel had set, the 
tape was removed on both sides and the bottom of the plate, and the plates were then clamped 
into the gel electrophoresis apparatus and the buffer chamber filled with 1x TBE running buffer 
(appendix II). Bromophenol blue dye (2μl) was added to each of the digested samples (half of 
the restriction digest mixture). An undigested sample was co-electrophoresed, as well as the 
λPst molecular weight marker. Electrophoresis was done at 12 V/cm at room temperature until 
a) 
b) 
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the bromophenol blue had migrated the length of the gel, which was subsequently silver stained 
as described in section 2.5.3.3. 
 
2.7 Statistical analysis 
Genetic association studies provide a useful approach to determine the effect of DNA variants 
in complex diseases (Risch and Merikangas, 1996). The success of the approach depends on the 
accuracy of measuring the allele frequency differences between the study group and a control 
population. However, the problem with this approach is the likehood of obtaining spurious 
associations when determining small genetic effects in large population structure that consists 
of individuals with different ancestry (Lander and Schork, 1994). The problem can be 
alleviated by using family-based association studies, which use the genotypes of parents of 
affected individuals to ensure that association between a marker allele and the phenotype is 
detected only if the marker is linked to a disease locus, even in the presence of population 
substructure (Spielman et al., 1993). In the present study, a transmission disequilibrium test 
(QTDT) was used to determine the association (if any) between identified polymorphisms and 
HCM phenotypes. 
 
2.7.1 Quantitative transmission disequilibrium tests (QTDT)  
QTDT is a family based test that is used to perform linkage disequilibrium and association 
analysis of quantitative traits in families of any size, optionally using parental genotypes 
(Abecasis et al., 2000). It requires a pair of matched data and pedigree files as input. Data files 
indicate the order in which QTDT would encounter sets of data in pedigree files. A pedigree 
file is a set of data collected for individuals between and within families. 
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Set up of QTDT data  
Parameters to be used in QTDT analysis were collected from the HCM files for each individual 
in the HCM families using Microsoft Excel. Quantitative traits that were used are as follows: 
interventricular septum (IVS), left ventricular mass (LVM), left ventricular posterior wall 
(LVPW), and left ventricular end diastolic diameter (LVED). The LVM was calculated 
according to the corrected American Society of Echocardiography formula: 
0.8×[1.04×(IVS+LVED+LVPW)3–LVED3]+0.6 (Devereux et al., 1986).  
 
Four pedigree files were created for LVM, IVS, LVPW, LVED and IVS + LVPW. In each file, 
each line which described an individual included a family identifier, a personal identifier, 
paternal (encoded by 1) and maternal (encoded by 2) identifiers, sex code (male- 1, female 2), 
quantitative traits (LVM, IVS, LVPW, IVS + LVPW and LVED) and polymorphisms (encoded 
as two consecutive integers) that were identified (ATF3P6_839, ATF3P5_1068, 
ATF3P5_1229, and ATF3P3_1617). The association was determined between the quantitative 
traits and polymorphisms with age and gender of genotyped individuals used as covariates, 
because the heart size is known to be influenced by gender, body mass and age of individuals 
(Harshfield et al., 1995). Body mass could not be included because of the lack of data in the 
clinical files of genotyped individuals. Pedigree files created for each quantitative trait were 
converted into standard text files (columns separated by tabs of spaces) that can be recognised 
by the QTDT program (Fig. 2.6).  
 
Running the QTDT program 
HCM families that were genotyped had multiple offspring and linear models do not provide a 
valid test of linkage disequilibrium in such cases (Allison et al., 1999). Therefore, a variance 
components model was used which allows the test to be conducted in families that have 
multiple offspring and it also takes into account environment, polygenic, and additive 
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components (Allison et al., 1999; Abecasis et al., 2000). The model requires an addition of 
inheritance-by-descent (ibd) files which were obtained by running simwalk2. Simwalk2 was set 
by running prelude for each pedigree file. The resulting statistics were collected into a single 
QTDT.ibd file by running finale IBD-01.*, and then the possibility of association between the 
quantitative traits and polymorphisms was determined with and without covariates. The prelude 
and finale programs were used to convert the data in the pedigree file into a format that is 
compatible with simwalk2. 
 
a) Data file without a covariate 
T LVM 
M P3_839 
M P5_1137 
M P5_1229 
M P6_1617 
 
b) Data file with a covariate 
T trait 
C1 covariate1 
C2 covariate2 
M P3_839 
M P5_1137 
M P5_1229 
M P6_1617 
Figure 2.6 Data files that correspond to the pedigree files that were created for the QTDT analysis. 
a) Data file without covariates. b)When covariates are included they follow traits (T) and covariates 
are followed by markers (M). 
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3.1 Genetic analysis of HCM, DCM and cardiac conduction system disorders 
The catalogue of genes previously identified as causes of HCM, DCM, or cardiac conduction 
system disorders is presented in tables 3.1 and 3.2. During the course of the study, complete 
sequences (DNA and protein sequences) of these genes were available in several databases 
under accession numbers that are also listed in the tables.  
 
3.2. Identification of candidate genes within the PFHBII locus 
3.2.1 BLAST hits to the PFHBII locus 
Nucleotide and protein sequences of the genes in the catalogue (tables 3.1 and 3.2) were used 
in BLAST analyses to search for genes at the PFHBII locus (chr 1: 206860725-209674431bp) 
with possible homologous functional and/or structural domains to them. No BLAST hits were 
identified within the PFHBII locus. Homologous sequences identified on chromosome 1 were 
all found outside of the PFHBII locus (tables 3.3 and 3.4).  
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Table 3.1 Chromosomal loci, genomic organisation, and accession numbers of sarcomeric and energy 
regulating protein-encoding genes implicated as causes of HCM and DCM. 
Disease Disease gene Locus Genomic organisation Accession 
number 
 Sarcomeric 
proteins 
   
HCM and DCM TNNT2 1q32 16 exons1 NM_000364 
HCM TNNI3 19q13 8 exons2 NM_000363 
HCM and DCM TPM1 15q22 9 exons3 M19713 
HCM and DCM MYH7 14q12 40 exons4 NM_000257 
HCM MYL3 3p21 7 exons5 NM_000258 
HCM MYL2 12q23-p21 7 exons6 S69022 
HCM and DCM ACTC 15q14 6 exons7 NM_005159 
HCM and DCM MYBPC3 11p11.2 35 exons8 Y10129 
HCM CRP3 11p15 5 exons9 NM_003476 
HCM and DCM TTN 2q31 363 exons10 NM_003319 
NM_133437 
NM_133432 
NM_133378 
 Energy-
regulating protein
   
HCM PRKAG2 7q36 16 exons11  AF087875 
Superscript numbers represent references for the sequences and genomic organisation: 1- Jing et al., 1992; 2- Bhavsar et al., 
1996; Barton et al., 1999, 3- MacLeod and Gooding, 1988; 4- Jaenicke et al., 1990; 5- Fodor et al., 1989; Kurabayashi et 
al., 1988; 6- Dalla Libera et al., 1989; 7- Strausberg, 2001 (direct submission) 8- Carrier et al., 1997, 9- Arber et al., 1994; 
Jetten, 1996 (direct submission), 10 Freiburg et al., 2000; Cazorla et al., 2000; Bang et al., 2001, 11- Lang et al., 2000. 
Abbreviations: TPM1- alpha tropomyosin gene; ACTC- cardic actin gene, CRP3- cardiac muscle LIM protein gene; 
MYBPC3- cardiac myosin binding protein-C gene, MYH7- cardiac myosin heavy chain gene, MYL3- essential myosin light 
chain gene, MYL2- regulatory myosin light chain gene; PRKAG2- 5’-AMP-activated protein kinase, gamma subunit gene, 
TNNI3- cardiac troponin I gene; TNNT2- cardiac troponin T gene. 
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Table 3.2 Chromosomal loci, genomic organisation, and accession numbers of cytoskeletal, 
sarcoplasmic reticulum, ion channel-, nuclear- and cytoplasmic protein-encoding genes identified as 
causes of DCM, HCM and CCS disorder accompanied by arrhythmia. 
Disease Disease gene Locus Genomic organisation Accession 
number 
 Cytoskeletal 
protein-encoding 
genes 
   
DCM DES 2q35 9 exons1 NM_001927  
DCM DMD Xp21.2 79 exons2 NM_004006 
DCM SGCD 5q33 8 exons3 NM_000337 
DCM Meta-VCL 10q22-q23 22 exons4 NM_014000 
 SR protein-
encoding gene 
   
DCM PLN 6q22.1 2 exons5 NM_002667 
 Nuclear protein-
encoding gene 
   
DCM LMNA 1q21.2-q21.3 12 exons6 NM_170707 
 Ion channel-
encoding gene 
   
CCS defects 
associated with 
arrhythmias 
SCN5A 3p21-p24 28 exons7 NM_000335 
 Cytoplasmic 
protein-encoding 
gene 
   
DCM G4.5 Xq28 11 exons8 NM_181314 
Superscript numbers represent references for the sequences and genomic organisation: 1- Li et al., 1989; Park et 
al., 2000, 2- Roberts et al., 1993; Koenig et al., 1987;  3- Nigro et al., 1996; Jung et al., 1996; 4- Koteliansky et 
al., 1992; 5- McTiernan et al., 1999, 6- Lin and Worman, 1993; , 7- Gellens et al., 1992, 8- Bione et al., 1996 
Abbreviations:CCS- cardiac conduction system; DES- desmin gene; DMD- dystrophin gene; G4.5- tafazzin 
gene; LMNA- lamin A/C gene; PLN- phospholamban gene; SCN5A- voltage gated sodium channel, type 5, alpha 
subunit gene; SGCD- deltasarcoglycan gene; SR- sarcoplasmic reticulum; VCL- metavinculin gene. 
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Table 3.3 Nucleotide sequence homologies of genes in the catalogue (tables 3.1 and 3.2) to 
positions on chromosome 1 and their scoring matrices. The PFHBII locus lies within 
chromosome 1: 206860725-209674431bp. 
Abbreviations: ACTC- actin gene, PRKAG2- 5’AMP-activated protein kinase, γ2 subunit gene, DES- desmin gene, DMD- 
dystrophin gene, LMNA- lamin A/C gene, meta-VCL- meta-vinculin gene, MYL2- myosin essential light chain 
gene, MYH7- myosin heavy chain gene, CRP3- muscle LIM protein gene, MYL3- myosin regulatory light chain 
gene, MYBPC3- cardiac myosin binding protein-C gene, PLN- phospholamban gene, SCN5A- voltage gated 
sodium channel, type 5, alpha subunit gene, SGCD- δ-sarcoglycan gene, G4.5- tafazzin gene, TNNI- troponin I gene, 
TNNT- troponin T gene, TTN- titin gene, TPM1- α-tropomyosin gene. *= the full coding sequence of titin was 
not available at the time of the study. 
 
 
 
 
 
 
Gene accession number Chromosome 1 locus e-value Percentage 
identity 
ACTC NM_005159 77662133 to 77662174 8.3e -127 85.71 
CRP3 NM_003476 198742132 to 198753688 6.8e -52 70.58 
DES NM_001927 153301537 to 153322820 6.6e-15 55.41 
DMD NM_004006 38963395 to 39162205 2.1e -12 59.62 
G4.5 NM_181314 67143243 to 67143472 3.2 59.02 
LMNA NM_170707 153301290 to 153301857 0 100.00 
Meta-VCL NM_014000 No match - - 
MYBPC3 NM_000256 200426296 to 200432989 7.8e -79 63.54  
MYH7 NM_000257 16327498 to 16334751 1.4e -07 58.96 
MYL2 S69022 No match - - 
MYL3 NM_000258 No match - - 
PLN NM_002667 114613339 to 114613643 1.0 57.72 
PRKAG2 AF087875 149300964 to 149301256 9.6 56.25 
SCN5A NM_000335 198315815 to 198318076 1.4e -19 62.56 
SGCD NM_000337 No match - - 
TTN NM_133432 
(novex-1 isoform) 
NM_133378 (N2-A 
isoform) 
225439641 to 225441264 
 
183284683 to 183301618 
3.2e-11 
 
5.4e-14 
60.00 
 
53.80 
TNNI3 NM_000363 198667721 to 198672641 3.4e -49 70.80 
TNNT2 AY277394 198616402 to 198616640 1.7e-140 100.00 
TPM1 NM_000366 151358569 to 151381283 2.2e -112 78.86  
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Table 3.4 BLASTP hits of genes in the catalogue (table 3.1) to positions on chromosome 1 and 
their scoring matrices. 
Gene Accession number Chromosome 1 locus e-value Percentage 
identity 
ACTC AAB59619 235131283 to 235132054 4.7e -107 79.84 
AMPK-γ2 NP_057287 36066720 to 36069724 1.5 32.63 
DES NP_001918 153317297 to 153322920 2.2e -25 28.78 
DMD NP_003997 39110150 to 39162448 8.6e -105 43.91 
LMNA NP_005563 153301502 to 153324272 1.1e-226 82.48 
Meta-VCL NP_054706 143311229 to 143315731 0.66 25.54 
MELC NP_000249 1796195 to 1796890 2.9e -13 33.10 
MHC NP_000248 16653976 to 16668348 3.6e -13 21.83 
MLP NP_003467 195177397 to 195178699 5.8e-4 34.48 
MRLC NP_000423 242192118 to 242197380 3.5e -08 31.63 
cMyBP-C NP_000247 198473136 to 198479070 1.4e -47 33.65 
PLB NP_002658 No match - - 
SCN5A NP_932173 178718998 to 178787734 2.1e -99 34.76 
SGCD NP_000328 No match - - 
TAZ NP_851831 21888484 to 21888540 4.7 47.37 
cTnI NP_000354 42456138 to 42886222 9.6 22.97 
cTnT AAP96757 198622582 to 198624248 2.9e-86 100.00 
TTN NP_597676 (novex-1 
isoform) 
 
NP_596869 (N2-A 
isoform) 
No match 
 
 
No match 
- 
 
 
- 
- 
 
 
- 
α-Tm NP_000357 15030968 to 15049730 1.3e-3 25.11 
Abbreviations: ACTC- actin, AMPK-γ2- AMP-activated protein kinase, γ2 subunit, DES- desmin, DMD- 
dystrophin,, LMNA- lamin A/C, Meta-VCL- meta-vinculin, MELC- myosin essential light chain, MHC- myosin 
heavy chain, MLP- muscle LIM protein, MRLC- myosin regulatory light chain, cMyBP-C- myosin binding 
protein-C, PLB- phospholamban, SCN5A- , SGCD- δ-sarcoglycan, TAZ- tafazzin, cTnI- troponin I, cTnT- 
troponin T, TTN- titin, α-Tm- α-tropomyosin 
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3.2.2 Genes identified using Ensembl and UCSC tools 
As no genes were identified at the PFHBII locus with domains that were homologous to the 
genes in the catalogue, the Ensembl and UCSC gene identification tools were used. These 
resources allow the user to view genes residing in defined chromosomal regions and provide 
detailed information about these genes through linkage with other databases, information that 
cannot be obtained directly through similarity searches. During the initial stages of the study, 
the human genome sequence was in a draft phase and gene annotation was still in progress 
but as the study progressed, more genes were mapped to the PFHBII locus. 
 
3.2.2.1 Ensembl gene identification tools 
Two genes, PFKFB2 and ATF3, were selected as strong candidates from the list of genes 
within the PFHBII locus that was obtained using the Ensembl genome browser. These genes 
were chosen as plausible candidates for both PFHBII-causing and HCM main locus and/or 
HCM modifying mutation analysis. The selection of PFKFB2 and ATF3 was based on the 
genome annotation data that was produced from the draft human genome sequence released in 
June 2001. At the time of the project, both genes were mapped to the PFHBII locus (Fig. 
3.1a) (http://www.ensembl.org) and therefore were entered into the mutation screening 
protocol. However, PFKFB2 and ATF3 were later mapped outside the PFHBII locus due to 
map refinements that occurred throughout the progress of the HGP (Fig. 3.1b) 
(http://www.ensembl.org).  
 
Apart from being candidate genes by position, these genes were also chosen as strong 
candidate genes because they are expressed in cardiac tissue and play an important role in 
cardiac function and/or development. PFKFB2 encodes a 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (PFK-2/FBPase-2) heart isoform, which catalyses the synthesis and 
degradation of fructose 2,6-bisphosphate, a potent stimulator of 6-phosphofructo-1-kinase 
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(PFK-1), which is a key enzyme of glycolysis (Heine-Suner et al., 1997). Glycolysis is one of 
the important energy generating processes in the heart. In addition, PFK-2/FBPase-2 is a 
substrate for AMPK, an enzyme important in ATP regulation and in which HCM-causing 
mutations have been described (section 1.5.2). 
 
ATF3 codes for activating transcription factor 3 (ATF3), which is a member of the 
mammalian activating transcription factor/cAMP responsive element-binding protein 
(ATF/CREB) family of basic region-leucine zipper (bZip) transcription factors (Hoeffler et 
al., 1988; Gonzalez et al., 1989; Hai et al., 1989; Foulkes et al., 1991). ATF3 homodimer is a 
transcriptional repressor, but its heterodimeric complex with other transcription factors (e.g., 
c-Jun, ATF2, JunB and gadd153/CHOP10) has been demonstrated to function as 
transcriptional activator (Hsu et al., 1992; Chu et al., 1994). ATF3 is a stress-inducable gene 
with its mRNA level greatly increased upon cell exposure to stress signals. ATF3 is induced 
in a variety of cell types by many different stress signals including myocardial ischemia-
reperfusion, renal ischemia-reperfusion, chemical toxicity in the liver and partial 
hepatectomy, suggesting that it may be a key regulator in cellular stress responses (Chen et 
al., 1996; Yin et al., 1997). The common feature about the signals that induce ATF3 is that 
they also induce cellular damage. Furthermore, expression of ATF3 in cardiac tissues of 
transgenic mice has been reported to lead to conduction abnormalities and contractile 
dysfunction, suggesting that ATF3 induction by stress signals may play a role in the 
pathogenesis of stress-associated cardiac diseases (Okamoto et al., 2001).  
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Figure 3.1 Cytogenetic map of chromosome 1q32.2-1q32.3. a) The positions of PFKFB2 and ATF3 
within the PFHBII locus according to the HGP data released on June 2001. b) The positions of 
PFKFB2 and ATF3 outside the PFHBII locus according to the current HGP data. The PFHBII locus 
is defined by markers D1S70 and D1S505, which are printed in black. The chromosome 1 band (chr 1 
band), DNA contigs, markers, and Ensembl known and novel genes are indicated. Abbreviations: 
ATF3- activating transcription factor 3 gene; CAMK1γ- calcium/calmodulin-dependent protein 
kinase type I; HSD11B1- 11-beta-hydroxysteroid dehydrogenase; LAMB3- laminin beta-3 chain 
precursor; IRF6- interferon regulatory factor 6; PFKFB2- 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 2; PPP2R5A- serine/threonine protein phosphatase 2A, alpha isoform. Adapted from the 
Ensembl database. Other genes in these diagrams did not have full names. 
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3.2.2.1.1 Genomic organisation of candidate genes 
PFKFB2 
PFKFB2 consists of 16 exons that encode a protein of 505 amino acids. PFK-2/FBPase-2 is a 
monomer divided into two functional domains, namely, the kinase and the phosphatase 
domains, with the kinase of the heart isoform regulated by the C-terminal regulatory domain 
(Kurland et al., 1992; Kutamura and Uyeda, 1988). Exons 3-8 encode the kinase domain and 
exons 9-14 the phosphatase domain and the regulatory domain is encoded by exon 15 (Fig. 
3.2) (Heine-Suner et al., 1998).  
 
 
 
 
 
 
 
Figure 3.2 Genomic organisation of PFKFB2. Bars and numbers represent exons. The functional 
domains are also indicated. 
 
ATF3  
ATF3 is encoded by four exons (A, B, C, and E) which are distributed over 15 kilobases 
(Liang et al., 1996) (Fig 3.3). The protein consists of three domains: the N-terminal domain, 
basic region, and the leucine zipper (ZIP) domain. ATF3 has an alternatively spliced isoform, 
ATF3ΔZip (Chen et al., 1994) which has an additional exon (exon D) that introduces an in-
frame termination codon resulting in a truncated protein (Fig. 3.3). 
 
 
     1    2 3   4   5   6     7           8 9     10   11    12  13   14          15  16 
kinase domain phosphatase domain C-terminal regulatory domain 
5’UTR 3’UTR
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Figure 3.3 Genomic organisation of a) ATF3 and b) ATF3ΔZip. Exons are represented by boxes 
labelled A, B, C, D, and E. Functional domains are indicated by boxes, the basic region and leucine 
zipper are labelled. The amino acids at the border are indicated. Abbreviation: Q- glutamine,Y- 
tyrosine, *= stop codon. Taken from Liang et al., 1996. 
 
3.2.2.2 UCSC gene identication tools 
Other strong candidate genes were identified using UCSC gene identification tools after the 
completion of the HGP, which was announced on 14 April 2003 (Fig. 3.5) (Collins et al., 
2003). Apart from being candidate genes by position, these genes were chosen because they 
are expressed in cardiac tissue and are functionally related to other genes that were reported to 
be important in heart function. The functions of these genes include apoptosis regulation, 
calcium binding, energy regulation (ATP transportation and phospholipid metabolism), signal 
transduction, and transcription regulation. Any protein defects that may interfere with these 
functions have been reported to disrupt cardiac function (discussed in chapter 1). The quality 
of the sequences of the genes was also verified so that they can be entered into future studies 
and screened for PFHBII-causing and HCM main locus and/or modifying mutations. 
 
                                    Basic Zip
A B C D  E 
     Basic L Q Y * 
1 167 411 519  717     1914 
mRNA
Protein 
mRNA
Protein
A B C                E 
ATF3 
ATF3Δ
Zip 
a) 
b) 
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Table 3.5 Strong candidate genes identified using UCSC gene prediction tools, their sequence 
status and predicted functions. 
Candidate gene Sequence status Predicted function 
G0S2 Complete Apoptosis regulator activity 
*FLJ25078  Complete  Calcium-binding mitochondrial carrier protein, 
ATP dependent transporter, nucleic acid binding 
IRF6 Complete Transcription factor 
*FLJ10876  Complete DNA binding, nuclear protein 
TRAF5 Complete Signal transduction 
*KIAA0205  
 
Complete Member of 10 acyl-SN-glycerol-3-phosphate 
acyltransferase family, phospholipid metabolism  
SLC30A1/ZNT1 Complete Zinc transporter 
NIMA-NEK2  Complete ATP-binding, regulation of mitosis  
RAMP zinc finger protein 
198 
Complete Regulation of transcription 
Abbreviations: IRF6- Interferon-receptor factor 6 gene; G0S2- putative lymphocyte G0/G1 switch gene; NIMA-
NEK2- Never in mitosis gene a-related kinase 2, TRAF5- Tumor necrosis factor receptor-associated factor 5 
gene; SLC30A1/ZNT1- solute carrier family 30 (zinc transporter), member 1 gene. Asterisks indicate predicted 
genes with no full names. 
 
3.2.3 Identification of promoter elements in the 5' region of PFKFB2 and ATF3 
3.2.3.1 PFKFB2 5' region  
The alignment of the 5’ region of the H. sapiens PFKFB2 with the R. norvegicus pfkfb2 
promoter region identified the positions of five reported or known transcription-binding sites 
(three Sp1- and two HNF1-binding sites) within a 500-bp PFKFB2 promoter region (Fig 3.4) 
(Heine-Suner et al., 1998). The positions of these transcription-binding sites were identified 
so that primers for amplification of this region could be designed and to enable analysis of 
PFHBII-causative and HCM main locus and/or modifying mutations. 
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  HUM   1201 ggtatgtatacaccctaaggcataattagctcaagtgttgtggtagttta   1250 
                        |||..||.....|.|||||||..|..||.||||||     
  RAT      1            accagaaattggagttagctcttgcattctggtag----     35 
 
  HUM   1251 ttctagcaaaaacatcttt-aaggcttacgttcccatttatggatctaat   1299 
               |.||| .|..||||||| ||.||..||||...|.||...|.|.|||   
  RAT     36 --ccagc-caggcatctttaaaagccgacgtctaccttccagaaccta--     80 
 
  HUM   1300 gaggttctgctgg-gattcaggaatgagagcgttaatctttgcagcattt   1348 
                ||...||||| |||||.||..|||..|||||||||.|   .|..||| 
  RAT     81 ---gtctagctggagattctggggtgaaggcgttaatcct---cgttttt    124 
 
  HUM    1349 tctcgtcacccggcacacccgctctcaagacgcctaccgaatagtctact   1398 
              |.|..|||||.|.|||.||  |.|.|||||.|.|..||.||.||.    | 
  RAT     125 ttttttcaccagtcactcc--cacgcaagatgtcagccaaacagg----t    168 
 
  HUM    1399 ctcgcgagagt-cagaaaaaagtcaagctttttattaacaccgcccccag   1447 
              |||||||||.| .|.||||||||.|.||||||.||||||.|||||..||| 
  RAT     169 ctcgcgagaataaaaaaaaaagtaaggcttttaattaaccccgccttcag    218 
 
  HUM    1448 ccctattagttaccaagcaacagtgccaccaggctc--ctcgg--cgctg   1493 
              |.|.|||.|||.||||||||||.||||||||.||||  ||.||  ||||| 
  RAT     219 ctcgatttgtttccaagcaacaatgccaccaagctctactgggtccgctg    268 
 
  HUM    1494 ----ggaaac--tcaggagcttgtgatctctctggttccgacttccagcc   1537 
                  ||.|.|  .|||  .|||..|.|.||.|.|||    .||.||||.| 
  RAT     269 ttttgggagcggacag--ccttaagctgtcacaggt----cctcccagac    312 
 
  HUM    1538 gccttcccgagccagttaggcgattgcgaccctgccccgccccctgggtc   1587 
                   |||         |||.|             |||||||||  ||.| 
  RAT     313 -----ccc---------aggag-------------cccgccccc--ggcc    333 
 
  HUM    1588 ctgcaggcgcccgattggtggatgattctctccaggtgaggacctacgcg   1637 
              |||||||.||...||||||..|...|.| ||||||||||||||..||||| 
  RAT     334 ctgcaggtgcttcattggtccagcgtgc-ctccaggtgaggactgacgcg    382 
 
  HUM    1638 cgagggggcggggccagacgggctcacatga-------------------   1668 
               |.|.|||||||.||...| |.|.|||.|||                    
  RAT     383 ggggtgggcgggcccgagc-gccccacgtgacacccccccccaacccccg    431 
 
  HUM    1669 ------------------tttgccggc----------gactgtagcgccg   1690 
                                |.||||.||          ..|.|..||.||| 
  RAT     432 gagcccggacttcttcagtctgcctgctcgctctgcttcccggcgctccg    481 
 
  HUM    1691 gt-------cccggccacaagc                               1750 
              ||       ||.||.|...|||                             
  RAT     482 gtggcgacaccgggtctacagcagggaggacgaataggacaggtcatagg    531 
 
 
Figure 3.4 Alignment of the 5’ flanking region of Homo sapiens PFKFB2 gene and exon 1c of 
Ratus norvegicus pfkfb2 gene. Conserved sequences that are similar to HNF1 and Sp1 consensus 
sites are shown in boxes. 
 
 
 
1
1
Sp1 
Sp1 
Sp1 HNF1 
HNF1 
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3.3 Mutation analysis of candidate genes 
3.3.1 Search for the PFHBII-causing mutation in the PFHBII family 
3.3.1.1 PFKFB2 
The coding exons of PFKFB2 (Fig 3.2) were analysed for the PFHBII-causing mutation using 
PCR-SSCP analysis. Two different electrophoretic patterns were identified in exon 8 in both 
unaffected and affected individuals (Fig. 3.5). No mobility shifts were detected in other exons. 
Two samples exhibiting different patterns were sequenced but no sequence variations were 
identified. Samples were re-analysed using the same methods (PCR-SSCP and automated 
sequencing) and similar results were obtained. The 500 bp-promoter region of PFKFB2 (Fig. 
3.4) was also analysed for possible PFHBII-causing mutation but no sequence variations were 
identified (Fig. 3.6). 
 
 
 
Figure 3.5 Representative PCR-SSCP analysis of exon 8 of PFKFB2 in the PFHBII family. Lanes 
1-3 = unaffected individuals, lanes 4-6 = affected individuals, lanes 7-10 = unaffected individuals 
from the general Afrikaner population. The arrows indicate two patterns, A and B, that were identified 
in the exon. No sequence variation could be identified to account for the different patterns detected in 
this exon. 
 
 
 
 
A B
1        2       3      4      5       6     7      8       9     10 
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Figure 3.6 Representative PCR-SSCP analysis of fragment 2 of the PFKFB2 promoter region in the 
PFHBII family. Lanes 1 and 2= unaffected individual, lanes 3 and 4= affected individuals. No 
mobility shifts were identified in this fragment. 
 
3.3.1.2 ATF3 
The ATF3 promoter and coding regions were analysed for the PFHBII-causative mutation in 
the PFHBII family but no sequence variations were identified in this gene. (Figs. 3.7 and 3.8). 
 
 
Figure 3.7 Representative mutation analysis of exon E of ATF3. Lanes 1-2= unaffected individuals, 
lanes 3-4= affected individuals. No mobility shifts were identified in this exon. 
 
 
Figure 3.8 Representative mutation analysis of fragment 3 of the ATF3 promoter region. Lanes 1-
2= unaffected individuals, lanes 3-4= affected individuals. No mobility shifts were identified in this 
fragment. 
 
1 2 3 4
1 2 3 4
1 2 3 4
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3.3.2 Search for HCM-causing and/or modifying mutations in the HCM panel 
3.3.2.1 PFKFB2 
Coding region 
The coding region of PFKFB2 was screened for HCM-causing and/or modifying mutations 
using PCR-SSCP analysis in a panel of 135 HCM-affected individuals. Different 
electrophoetic mobility patterns were only identified in exons 5 and 8. Three different 
electrophoretic mobility patterns were identified in exon 5 (Fig. 3.9). One pattern was found 
in individual 445 (lane 5 in figure 3.9), the second pattern was found in four of the individuals 
analysed (three of these individuals, 3352, 2712 and 1508 are indicated in lanes 1-3), and the 
third pattern (lane 4) was found in the remaining 129 individuals of the HCM panel. The three 
amplicons with these different patterns were subsequently sequenced, and the obtained 
sequences were compared with the GENBANK sequence (accession number: AJ005577) to 
determine the presence or absence of sequence variations. A G→A transition substitution was 
identified in a sample sequence of individual 445 (Fig. 3.10) at position 11535 of the genomic 
sequence of PFKFB2. However, the substitution did not result in an amino acid change. This 
substitution is similar to the one deposited by other investigators in the NCBI-SNP database 
under the SNP ID number rs2629639. No sequence variation could be identified in the 
amplicon of individual 2712 to account for the variant pattern identified in lanes 1-3. The 
sequence of the amplicon representing the third pattern was similar to that of exon 5 of the 
published sequence. 
 
Two patterns similar to those identified in the PFHBII family (Fig. 3.5) were also identified in 
exon 8 in the HCM panel (data not shown) but again no sequence variations were identified.  
 
 
 
  
90
 
 
Figure 3.9 Representative PCR-SSCP analysis of exon 5 of PFKFB2 in the HCM panel. The arrows 
indicate three different patterns that were identified in the HCM panel. Lane 1=3352, lane 2= 2712, 
lane 3= 1508, lane 4= 2557 and lane 5= 445. The variant pattern caused by the G→A transition 
substitution identified at position 11535 is indicated in lane 5. No sequence variation could be 
identified to account for the variant pattern identified in lanes 1-3. No sequence variant was identified 
in the sequence of individual 2557 represented in lane 4 
 
 
 
GENBANKPFKEx5    GGCGCTGGAAGATGTTAAGGCGTATCTCACTGAGGAGAA 
Ex5445F          GGCGCTGGAAGATGTTAAGGCRTATCTCACTGAGGAGAA 
RevCompEx5445    GGCGCTGGAAGATGTTAAGGCRTATCTCACTGAGGAGAA 
 
ACAGTGTGCTCTGGTGGCGCTGGAAGATGTTAAGGCGTATCTCACTGAGGAGAATGGTCA 
  Q  C  A  L  V  A  L  E  D  V  K  A  Y  L  T  E  E  N  G  Q 
 
ACAGTGTGCTCTGGTGGCGCTGGAAGATGTTAAGGCATATCTCACTGAGGAGAATGGTCA 
  Q  C  A  L  V  A  L  E  D  V  K  A  Y  L  T  E  E  N  G  Q 
 
Figure 3.10. Representative mutation analysis of exon 5 of PFKFB2 in individual 445. 
Chromatogram representing the partial nucleotide sequence of a) individual 2557 (GG genotype) and 
b) individual 445 (G/A variant) with the position of the sequence variation indicated by an arrow. 
Below is the CLUSTAL aligment of the GENBANK PFKFB2 sequence and the forward and reverse 
complementary sequences of individual 445. Translation of the two sequences is also shown with the 
affected codon written in colour. R refers to G/A heterozygote.Abbreviations: NCBIPFKEx5- exon 5 
of the GENBANK sequence, Ex5445F- forward sequence of PFKFB2 exon 5 of individual 445, 
RevComplEx5445- reverse complementary sequence of exon 5 of individual 445 
a) 
b) 
GENBANK sequence 
445 protein sequence 
1        2          3         4           5
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Promoter region 
The PFKFB2 promoter region was also analysed for HCM main locus and/or modifying 
mutations but no sequence variations were identified (Fig. 3.11).  
 
 
Figure 3.11 Representative PCR-SSCP analysis of fragment 2 of the PFKFB2 promoter region in 
the HCM panel. Lanes 1-3 represent some of the HCM-affected individuals in the panel that were 
analysed. No mobility shifts were identified in this region. 
 
 
3.3.2.2 ATF3 
Coding Region 
No mobility shifts were identified in the coding exons (exons B, C, and E) of ATF3 (Fig. 3.3) 
analysed in the HCM panel (Fig. 3.12). 
 
 
Figure 3.12 Representative mutation analysis of exon E of ATF3 in the HCM panel. Lanes 1-2= 
unaffected individuals, lanes 3-4= affected individuals. No mobility shift were identified in this exon as 
indicated in the diagram 
 
 
 
1  2  3 
1 2 3 4
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Promoter Region 
The ATF3 promoter region was also analysed for HCM-causing and/or modifying mutations 
in the HCM panel. Mobility shifts were identified in four  of the fragments (fragments 3, 5, 6, 
and 8). 
 
Fragment 3  
Two different electrophoretic mobility patterns were identified in fragment 3 of ATF3 
promoter region in the HCM panel: 14 individuals demonstrated the pattern shown in lane 2 
of figure 3.13 while the remaining 133 had a pattern that is shown in lane 1 of figure 3.13. 
Two analysed DNA samples representing these different patterns were subsequently 
sequenced and the obtained sequences were aligned with the GENBANK sequence (accession 
number: U37542). At position -1688 a C was identified in all three amplicons that were 
sequenced not a T, as recorded in the GENBANK sequence (Fig. 3.14,b2). A second 
transition substitution (-1617A/G) (Fig. 3.14, b1) was identified in one of the obtained 
sequences represented in lane 2 of figure 3.13. Fragment 3 of the ATF3 promoter region was 
analysed further in families of the probands in the HCM panel to determine the segregation of 
these sequence variants using both PCR-SSCP analysis and ASREA (Figs. 3.20-3.22 ), and 
similar variant patterns were identified.  
 
 
Figure 3.13 Representative PCR-SSCP analyses of ATF3 promoter region, fragment 3 in the HCM 
panel. The arrows indicate the two different electrophoretic patterns identified in the HCM panel. 
Lanes 1 = individual with -1617A/A genotype, lanes 2 = individual with -1617A/G genotype (see 
figure3.15). 
1     2 
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GENBANK seq       CGCGTGGAACTCCAGGGCTCCCGGGTCCGCCGGGGCGCAAAGACTTCCGAGGCCGCCCTC 
p32829F           CGCGTGGAACCCCAGGGCTCCCGGGTCCGCCGGGGCGCAAAGACTTCCGAGGCCGCCCTC 
p32829Rev_Compl   CGCGTGGAACCCCAGGGCTCCCGGGTCCGCCGGGGCGCAAAGACTTCCGAGGCCGCCCTC 
 
published atf3    CGCGTGTTCCCAGGCCCGTGGAGAGGTGGGTGGTCTGAGTGAGGTCGGGCTTGGCGGCGA 
p32829F           CGCGTGTTCCCAGGCCCGTGGRGAGGTGGGTGGTCTGAGTGAGGTCGGGCTTGGCGGCGA 
p32829Rev_Compl   CGCGTGTTCCCAGGCCCGTGGRGAGGTGGGTGGTCTGAGTGAGGTCGGGCTTGGCGGCGA 
Figure 3.14 Representative mutation analysis of the ATF3 promoter region, fragment 3 in the HCM 
panel. The chromatographs represent the partial sequences of two individuals in the HCM panel with 
variant patterns. a) the 1617A/A genotype, b1) -1617A/G genotype, and b2) -1688C/C genotype. 
Below the chromatogram is the alignment of the GENBANK sequence, and the forward and reverse 
complementary sequences obtained from automated sequencing. R refers to the A/G heterozygote. 
Abbreviations: seq- sequence, p32829F- forward sequence of an amplicon of individual 2829 in lane 
2, p32829Rev_Compl- reverse complementary sequence of an amplicon of individual 2829. 
 
 
Fragment 5 
Three different patterns were identified in individuals in fragment 5 of ATF3 promoter region 
in the HCM panel (lanes 1, 2, and 3 in figure 3.15) and three amplicons with different patterns 
were subsequently sequenced. The obtained sequences were aligned with GENBANK 
sequence (accession number: U37542) to determine either the presence or absence of 
sequence variations. A G→C transversion substitution was identified at position –1068 (-
a) 
b1) 
b2) 
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1068G/C) (Fig. 3.16) in all three sequenced amplicons. A similar SNP was deposited by other 
authors in the NCBI-SNP database and is available under the SNP-ID number rs4951627. The 
second variant, a C→T transition substitution, was identified at position –1229 of the ATF3 
promoter region (-1229C/T) (Fig 3.16) in one of the sequenced amplicons (lane 3). No 
additional sequence variations were identified in the third amplicon (lane 2) (Fig 3.17), 
though it appeared different from other amplicons in the SSCP gel. Fragment 5 of the ATF3 
promoter region was analysed further in families of the probands in the HCM panel to 
determine the segregation of the identified variants using both the PCR-SSCP analysis and 
ASREA (Figs. 3.20-3.22) and similar electrophoretic patterns were identified.  
 
 
Figure 3.15 Representative PCR-SSCP analysis of ATF3 promoter region, fragment 5 in the HCM 
panel. The arrows indicate the three patterns identified in the HCM panel. Lanes 1 and 2 = 
individuals with the -1229C/C genotype, lanes 3= individuals with the -1229C/T genotype (see 
section 3.4.2). No additional sequence variation was identified to account for the third pattern 
in lane 3. 
 
 
 
 
 
 
 
1 2 3
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GENBANK seq        AAGAACCAGGAAATCGTTTTTAAGGTTCAAACCCAGTTCTGCTGAGGTCTCAGCTCGAA 
p51031F                        ANNNNNTTTTTAGGTNNAACCCAGTTCTGCTGAGGTCTRAGCTCGAA 
p51031 Rev_Compl  TAAGAACCAGGAAATCGTTTTTAAGGTTCAAACCCAGTTCTGCTGAGGTCTRAGCTCGAA 
 
publ.atf3promoter TCTCGGACCACGGGGCCCCGCCTTTCCCGCCACCCTGGCTTGAGGGCAGAGGGGATTTCT 
p51031F           TCTCGGACCACGGGGCCCCGCCTTTCCCGCCACCCTGGCTTGAGGGCAGAGGGGATTTCT 
p51031 Rev_Compl   TCTCGGACCACGGGGCCCCGCCTTTCCCGCCACCCTGGCTTGAGGGCAGAGGGGATTTCT 
 
publ.atf3promoter GCTGCGGGTTCCGCCTGTGGTCAGTGCGTCCCCATTCCGGGCCGTCCGGTCCCAGTCCAA 
p51031F           GCTGCGGGTTCCGCCTGTGGTCAGTGCGTCCCCATTCCGGGCCGTCCGGTCCCAGTCCAA 
p51031            GCTGCGGGTTCCGCCTGTGGTCAGTGCGTCCCCATTCCGGGCCGTCCGGTCCCAGTCCAA 
 
publ.atf3promoter  TCGGCTCTGGGAGCAGAAGAACACGTGAAAGCTGAAGATGGGTTTTCCCTAAATATTGCC 
p51031F            TCGGCTCTGGGAGCAGAAGAACACGTGAAAGCTGAASATGGGTTTTCCCTAAATATTGCC 
p51031 Rev_Compl   TCGGCTCTGGGAGCAGAAGAACACGTGAAAGCTGAASATGGGTTTTCCCTAAATATTGCC 
Figure 3.16 Representative mutation analysis of the ATF3 promoter region, fragment 5 in the 
HCM panel. The chromatographs represent the partial sequences of two individuals in the HCM 
panel with different electrophoretic  patterns. a) a chromatogram of a reverse sequence of fragment 5 
of ATF3 promoter region showing the -1229C/T variant b) a chromatogram of a reverse sequence of 
the same fragment showing the -1068G/C variant (indicated by arrows). Below the chromatogram is 
the alignment of the GENBANK sequence, and the forward and reverse complementary sequences 
obtained from ABI traces. R refers to the C/T heterozygote, S refers to the G/C heterozygote. 
Abbreviations: seq- sequence, p51031F- forward sequence of an amplicon of individual 1031 in lane 
3, p51031Rev_Compl- reverse complementary sequence of an amplicon of individual 1031. 
 
 
 
 
b) 
a) 
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atf3ucsc promoter TCGGCTCTGGGAGCAGAAGAACACGTGAAAGCTGAAGATGGGTTTTCCCTAAATATTGCC 
P53776 REV.COMP   TCGGCTCTGGGAGCAGAAGAACACGTGAAAGCTGAASATGGGTTTTCCCTAAATATTGCC 
P53776F           TCGGCTCTGGGAGCAGAAGAACACGTGAAAGCTGAASATGGGTTTTCCCTAAATATTGCC 
Figure 3.17 Representative mutation analysis of ATF3 promoter region, fragment 5 in the HCM 
panel. The chromatograph represents the partial sequences of the third amplicon (lane 3 in figure 
3.16).The 
 -1068G/C substitution is indicated by an arrow. Below the chromatogram is the alignment of the 
GENBANK sequence, and the forward and reverse complementary sequences obtained from 
automated sequencing. The sequence variation is written in colour. No additional sequence variation 
was identified although this amplicon in SSCP gel appeared different to other patterns. S refers to the 
G/C heterozygote. Abbreviations: seq- sequence, p53776F- forward sequence of an amplicon of 
individual 1031 in lane 2, p53776Rev_Compl- reverse complementary sequence of an amplicon of 
individual 3776. 
 
 
Fragment 6 
Two different electrophoretic patterns were identified in fragment 6 of the ATF3 promoter 
region in individuals in the HCM panel: one pattern is shown in lane 1 and another pattern in 
lane 2 (Fig. 3.18). An amplicon with each pattern was subsequently sequenced and the 
obtained sequences were aligned with the GENBANK sequence. A T→A transversion 
substitution was identified at position –839 of the ATF3 promoter region (-839T/A) (Fig. 
3.19). Fragment 6 of the ATF3 promoter region was analysed further in families of the 
probands in the HCM panel to determine the segregation of the variant (Figs. 3.20-3.22), and 
similar variant patterns were identified.  
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Figure 3.18 Representative PCR-SSCP analysis of ATF3 promoter region, fragment 6 in the HCM 
panel. the arrows indicate two variant patterns identified in individuals in the HCM panel. Lane 1= 
individuals with -839T/T genotype, lane 2 = -839T/A genotype. 
 
 
 
 
GENBANK seq    CTTGTCAATTTCAAACGCTTTGTGATTGTAAAAAAAAAAAAATCGAACCGATACGGTCCT 
Rev Comp       CTTGTCAATTTCAAACGCTTTGTGATTGTAAAAAAAAAAAAAWCGAACCGATACGGTCCT 
P6Forward      CTTGTCAATTTCAAACGCTTTGTGATTGTAAAAAAAAAAAAAWCGAACCGATACGGGCCT 
Figure 3.19 Representative mutation analysis of ATF3 promoter region, fragment 6 in the HCM 
panel. The chromatographs represent the partial sequences of two amplicons with different 
electrophoretic patterns. a)  -839T/T genotype, b) -839T/A genotype. The position of the sequence 
variant is indicated by an arrow. Below the chromatogram is the alignment of the GENBANK 
sequence, and the forward and reverse complementary sequences obtained from automated 
sequencing. The sequence variation is written in colour. W refers to the T/A heterozygote. 
Abbreviations: Rev Comp- reverse complementary, seq- sequence 
 
b) 
a) 
1 2
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Figure 3.20 Pedigree 101, which was investigated for the segregation of single nucleotide changes identified in fragments 3, 5 and 6 of the ATF3 promoter region. The 
family was reported in previous studies as carrying the MYH7-Ala797Thr mutation (Moolman et al., 1998; Moolman et al., 2000). Allele definition: ATF3P6_839- 1=T, 
2=A; ATF3P5_1068- 1=G, 2=C; ATF3P5_1229- 1=C, 2=T; ATF3P3_1617- 1=A, G=2. 2= 2/2 and 1= 1/1. Symbol definition: Open symbols indicate individuals with 
unknown clinical status; solid symbols indicate affected subjects; plus symbol indicate MYH7-Ala797hr mutation carriers, open symbol with a dot indicates MYH7-Ala797hr 
mutation carriers but not clinically affected; diagonal lines indicate deceased individuals. The order of the marker genotypes, from the telomere to the centromere, is 
indicated in the box at the top of the diagram. 
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Figure 3.21 Pedigree 106, which was investigated for the segregation of single nucleotide changes identified in fragments 3, 5 and 6 of the ATF3 promoter region. The 
family was reported in previous studies as carrying the MYH7-Arg403Trp mutation (Moolman et al., 1998; Moolman et al., 2000). Allele definition: ATF3P6_839- 1=T, 
2=A; ATF3P5_1068- 1=G, 2=C; ATF3P5_1229- 1=C, 2=T; ATF3P3_1617- 1=A, G=2. 2= 2/2 and 1= 1/1. Symbol definition: Open symbols indicate individuals with 
unknown status; N indicates unaffected individuals; solid symbols indicate affected subjects; plus symbol indicates the MYH7-Arg403Trp mutation carriers, open symbol 
with a dot indicates the MYH7-Arg403Trp mutation carriers but not clinically affected; diagonal lines indicate deceased individuals. The order of the marker genotypes, 
from the telomere to the centromere, is indicated in the box at the top of the diagram. 
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Figure 3.22 Pedigree 108, which was investigated for the segregation of single nucleotide changes identified in fragments 3, 5 and 6 of the ATF3 promoter region. The 
family was reported in previous studies as carrying the MYH7-Arg249Glu mutation (Moolman et al., 1998; Moolman et al., 2000). Allele definition: ATF3P6_839- 1=T, 
2=A; ATF3P5_1068- 1=G, 2=C; ATF3P5_1229- 1=C, 2=T; ATF3P3_1617- 1=A, G=2. 2= 2/2 and 1= 1/1. Symbol definition: Open symbols indicate individuals with 
unknown status; N indicates unaffected individuals; solid symbols indicate affected subjects; plus symbol indicates MYH7-Arg249Glu mutation carriers, open symbol with a 
dot indicates MYH7-Arg249Glu mutation carriers but not clinically affected; diagonal lines indicate deceased individuals. The order of the marker genotypes, from the 
telomere to the centromere, is indicated in the box at the top of the diagram. 
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Fragment 8 
Two different patterns were identified in individuals in the HCM panel, one in lane 1 and 
another in lane 2 (Fig. 3.23). Amplicons of individuals with these patterns were subsequently 
sequenced and an A→G transition substitution was identified at position -282 in both 
sequences obtained (Fig. 3.24). Genotypes of probands in the HCM panel and their family 
members could not be determined using ASREA because the variant did not affect a 
restriction enzyme recognition site. 
 
 
Figure 3.23 Representative PCR-SSCP analysis of ATF3 promoter region, fragment 8 in the HCM 
panel. The arrows indicate variant patterns identified in HCM-affected individuals in the HCM panel.  
 
 
GENBANK seq     CCGGTCCTGATATGGAGAGAGA 
P8927F          CCGGTCCTGATRTGGAGAGAGA 
P8927Rev.Comp   CCGGTCCTGATRAGGAGAGAGA 
Figure 3.24Representative mutation analysis of ATF3 promoter region, fragment 8 in the HCM 
panel. The -282A/G variant is indicated by an arrow. Below is the CLUSTAL alignment of the 
GENBANK ATF3 promoter sequence, and the forward and reverse complementary sequences 
obtained from the automated sequencing. R refers to the A/G heterozygote. 
 
1        2 
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3.4 Allele-specific restriction enzyme analysis  
-1229C/T and -1068G/C variants 
Two of sequence variations, -1068G/C or -1229C/T, identified in fragment 5 of the ATF3 
promoter region (Fig. 3.16) affected the restriction enzyme recognition site resulting in a gain 
of an NlaIII site or a loss of an Alw26I site, respectively (Figs. 3.25 and 3.26) (Fig. 2.5 for a 
detailed restriction map). This digestion was therefore used to verify the genotypes of the 
analysed individuals.  
 
 
 
Figure 3.25 Genotyping of HCM-affected individuals at position -1068 of the ATF3 promoter for 
the G/C transition substitution. The amplified promoter fragment was digested with NlaIII and size-
separated by electrophoresis on a 12% polyacrylamide gel. The C allele resulted in a gain of 
an NlaIII recognition site as indicated by the presence of a 227-bp fragment. Lane 1 = λPst, 
lane 2 = undigested amplicon, lane 3 = GG, and lane 4 = GC.The faint band in lane 3 is caused by 
overflowing of the amplicon in lane 4. b) Schematic representation of the amplified fragment showing 
the position of the NlaIII site. *= variable restriction enzyme site. 
 
 
 
1 2 3 4
339bp 
300bp
200bp 
73bp
72bp 
227bp
 *N 
227bp 73bp
a) 
b)
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Figure 3.26 Genotyping of HCM-affected individuals at position -1229 of the ATF3 promoter for 
the C/T substitution. a) The amplified promoter fragment was digested with an Alw26I and size-
separated by electrophoresis on a 12% polyacrylamide gel. The T allele resulted in a loss of 
an Alw26I recognition site as indicated by the presence of the 300-, 234-, and 66-bp 
fragments in the CT genotype in lane 4. Lane 1 = λPst, lane 2 = undigested amplicon, lane 3 = 
C/C, and lanes 4 = CT. The second band in lane 2 is caused by overflowing of the amplicon in lane 3. 
b) Schematic representation of the amplified fragment showing the position of the Alw26I site. *= 
variable restriction enzyme site. 
 
3.5 Summary of mutation analysis of the ATF3 promoter region 
In summary, from the genotype analysis of HCM-affected individuals in the HCM panel, the 
following data was obtained: the -1617A/A and -1617A/G genotypes were detected in 
fragment 3; the -1068G/C- -1229C/C, -1068G/C- -1229C/T, -1068G/G- -1229C/C and -
1068G/G- -1229C/T genotypes in fragment 5 and the -839T/T and -839T/A genotypes in 
fragment 6.  
 
1 2 3 4
66bp
72bp 
234bp
300bp
339bp 
66bp 234bp 
*A
a)
b) 
300bp 
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3.6 QTDT analysis 
Transmission disequilibrium tests, such as QTDT, estimate whether preferential transmission 
of one allele at a polymorphic locus occurs between affected parent and affected children 
within a family (Abecasis et al., 2000). As such, these tests require that at least one of a set of 
parents in each nuclear family be heterozygous at the polymorphic locus. The QTDT program 
requires that at least 30 individuals in the given dataset be heterozygous before analysis 
commences. Although all ATF3 promoter polymorphisms identified in the study were 
genotyped in the families of the probands (Figs. 3.20-3.22), only the -839T/A polymorphism 
was informative enough in these families to allow statistical analysis. The p-values obtained 
indicated that there is no significant association between this marker and the HCM-related 
traits (table 3.6). The analysis was corrected for age and gender as these covariates can affect 
the statistical values, and again no association was detected. 
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Table 3.6 p values for TDT of the ATF3 -839T/A polymorphism and HCM-related 
quantitative traits. 
Marker/SNP Quantitative trait  Number of 
individuals tested 
P value 
(before 
correction) 
P value 
(overall 
Bonferroni 
significant 
level) 
-839T/A LVM_age_gender  
 
LVM 
34 out of 76 
individuals 
0.2609 
 
0.1423 
0.4537 
 
0.2643 
 IVS_age_gender 
 
IVS 
34 out of 76 
individuals 
0.5994 
 
0.5010 
0.8395 
 
0.7510 
 LVPW_age_gender 
 
LVPW 
34 out of 76 
individuals 
0.4464 
 
0.5284 
0.6936 
 
0.7776 
 LVED_age_gender 
 
LVED 
34 out of 76 
individuals 
 
0.4820 
 
0.6678 
0.7316 
 
0.8897 
 PW+IVS_age_gender 
 
PW+IVS 
34 out of 76 
individuals 
 
0.3357 
 
0.2978 
0.5588 
 
0.5069 
Abbreviations: IVS- interventricular septum, LVM- left ventricular mass, LVED- left ventricular end diastolic 
diameter, LVPW- left ventricular posterior wall, PW- posterior wall. The first line in each row is trait corrected 
for covariates age and gender. The second line is trait alone. 
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4.1. Identification of candidate genes within the PFHBII Locus  
The present study sought to identify the molecular aetiology of PFHBII, a DCM-associated 
disorder complicated by cardiac conduction defects, which segregates in a South African 
Caucasian Afrikaner family (Brink and Torrington, 1977). To this end, plausible candidate 
genes were identified within the PFHBII locus and screened for a possible disease-causative 
mutation. In addition, these candidate genes were screened for HCM main locus and/or HCM 
modifying mutations based on the premise discussed in chapter 1 (section 1.7). Several 
strategies have been implemented to identify PFHBII candidate genes, of which two were 
sequence alignment analyses (BLAST) and data-mining of gene annotation databases 
(Ensembl and UCSC). Although no sequence homologies to the genes previously identified as 
causes of DCM, cardiac conduction disorders associated with arrhythmia or HCM were 
identified by BLAST homology searches at the PFHBII locus, eleven plausible PFHBII 
candidate genes were selected from this region using the Ensembl and UCSC gene 
identification tools (table 3.5).  
 
Two genes, PFKFB2 and ATF3, were screened for both PFHBII-causing and HCM main locus 
and/or modifying mutations using PCR-based SSCP and nucleotide sequence analyses. No 
PFHBII-causing mutation was identified upon analysis of subjects from the PFHBII-affected 
family in either PFKFB2 or ATF3. Furthermore, recent database analysis indicated that 
PFKFB2 and ATF3 were mapped outside the PFHBII locus. Therefore, the two genes were 
excluded as cause of PFHBII by position, as well as by extensive mutation analysis of exons, 
exon/intron junctions and promoter sequences. Additionally, several sequence variants were 
identified in both candidate genes in the HCM panel: one variant was identified in the coding 
region of PFKFB2, and six variants were identified in the ATF3 promoter region, however, 
they were not HCM main locus mutations. Insufficient data was generated in a pilot study to 
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draw conclusions about their role as HCM modifying mutations. Results obtained in the 
present study are discussed below. 
 
4.1.1 Preparing a catalogue of genes previously identified as causes of HCM, DCM, and 
cardiac conduction disease 
A catalogue of genes previously identified as cause of HCM, DCM, and conduction defects 
was prepared using published material and database resources. The catalogue consisted of the 
genes and associated diseases, the chromosomal locus of each gene, its genomic organisation 
and the accession number of the individual gene (refer to tables 3.1 and 3.2). Complete 
nucleotide and protein sequences of the genes in the catalogue are available in NCBI 
GenBank, Ensembl and UCSC, and can be retrieved using their accession numbers as 
identifiers. During the course of the study, the catalogue was continuously updated as new 
information about genes was obtained from published data and databases.  
 
4.1.2 BLAST search 
Sequences of the genes in the catalogue were used as queries to identify genes with 
homologous functional domains within the PFHBII locus. Although a number of gene 
identification strategies could be employed to identify candidate genes at a locus, it was opted 
to use BLAST homology searches in the present study. This approach was utilised because 
BLAST provides freely available, yet powerful, bioinformatics tools for performing functional 
analysis of a novel gene by comparing its sequence with that of genes that encode proteins 
with known structure and/or function (Altschul et al., 1990; Pearson, 1996). Genes previously 
identified as cause of DCM and HCM were used due to the fact that a primary form of 
cardiomyopathy is one of the clinical features of PFHBII (see section 1.3.3). Additionally, the 
identification of DCM-causing mutations in genes in which certain mutations had previously 
been reported as cause of HCM has resulted in speculation that there may be common 
  
109
pathological pathways among these two forms of cardiomyopathy (Olson et al., 2001; 
Moolman-Smook et al., 2003). Therefore, we hypothesised that any gene within the PFHBII 
locus that is structurally and/or functionally related to the genes implicated as causing DCM or 
HCM is a plausible candidate for PFHBII mutation analysis.  
 
In the present study, the BLAST analyses indicated that there were no genes within the 
PFHBII locus with homologous functional domains to those in the catalogue, or that they were 
missed as the program uses sequence similarities to identify related proteins. BLAST searches 
were performed after the release of the second draft sequence of the Human genome (June 
2001) and again after the announcement of the completion of the HGP (14 April 2003), at the 
time when genes were still being annotated. Thus, it is possible that, when the searches were 
performed, a newly identified gene/protein signature was not yet entered into one of the HGP 
databases and, therefore, no reference to its unique sequence existed in the database. 
 
The disadvantage of using the BLAST program to identify biologically related genes or 
proteins is its inability to identify distantly related genes or proteins (Brenner et al., 1998; Park 
et al., 1998). The limitation of the BLAST homology searches is also made apparent by its 
inability to identify the structural similarity between hemoglobin and myoglobin, which are 
considered to be biologically related although they have very low sequence similarity (Brenner 
et al ., 1998). It has been reported that protein classification is not only based on sequence 
identity, but also on structural details, folding of proteins and functional features (Park et al., 
1998). Proteins with domains that have close evolutionary relationships (i.e., high sequence 
identity) are grouped into one family and those that have low sequence identity but whose 
structural details and functional features suggest an evolutionary origin, are grouped into 
superfamilies (Park et al., 1998). Although profile-based techniques such as PSI-BLAST 
(Altschul et al., 1997), Hidden-Markov models (Karplus et al., 1998) and structure-based 
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techniques such as ENVIRON (Bordo, 1993) were developed for identifying distantly related 
proteins, these tools are limited by the lack of structural and functional data of several newly 
annotated proteins in databases (Koppensteiner et al., 2000).  
 
4.1.3 Ensembl and UCSC gene identification tools 
These tools were used because, apart from providing information about a gene’s chromosomal 
location, they also allow access to a lot of information related to the function of the gene’s 
product and tissue expression profile.  
 
4.1.3.1 Ensembl gene identification tools 
At the start of the study (June 2001), two attractive candidate genes, PFKFB2 and ATF3, were 
identified within the PFHBII locus and were therefore entered into the mutation screening. The 
rationale for selecting PFKFB2 and ATF3 as PFHBII and HCM plausible candidate genes is 
discussed below. 
 
PFKFB2 
Apart from apparently being a PFHBII plausible candidate gene by position at the start of the 
study, PFKFB2 was chosen for its expression in cardiomyocytes and for its role in energy 
metabolism. PFKFB2 encodes a PFK-2/FBPase-2, which catalyses the synthesis and 
degradation of fructose-2,6-bisphosphate (Fru-2,6-P2). PFK-2/FBPase-2 regulates glycolysis 
through its substrate, Fru-2,6-P2, that stimulates 6-phosphofructo-1-kinase (PFK-1) activity 
(Hasemann et al., 1996). PFK-1 is a key glycolytic enzyme, which catalyses the first reaction, 
phosphorylation of fructose-6-phosphate, that commits glucose to glycolysis (Depré et al., 
1998). PFK-2/FBPase-2 has been reported to be a substrate for AMPK, an enzyme encoded by 
PRKAG2, the gene in which HCM-causative mutations have been identified (Blair et al., 
2001). PFK-2 activation by AMPK is correlated with AMPK activation under anaerobic 
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conditions. The AMPK-mediated activation of PFK-2/FBPase-2 stimulates the flux through 
PFK-1 by increasing the concentration of Fru-2,6-P2, which, in turn, stimulates ATP 
production through glycolysis. The involvement of protein phosphorylation in the Pasteur 
effect is superimposed on the direct stimulation of PFK-1 by an increase in intracellular 
AMP:ATP ratio (Marsin et al., 2000). This indicates that PFK-1 stimulates glycolysis through 
two mechanisms: a direct allosteric stimulation by an increase in the AMP:ATP ratio and an 
indirect mechanism involving the phosphorylation of PFK-2/FBPase-2 by AMPK. 
 
AMPK has also been reported to play a role in the regulation of ATP production. The enzyme 
acts as a sensor of the energy state through its activation, like PFK-1, by an increase in the 
intracellular AMP:ATP ratio. AMPK phosphorylates and inactivates enzymes in energy-
consuming biosynthesis pathways, such as synthesis of fatty acids, cholesterol, glycogen and 
phosphocreatine, to conserve ATP. It has been suggested that alterations in cellular energy 
homeostasis may be the underlying pathophysiolocal mechansism in DCM and HCM 
(Ashrafian et al., 2003). Therefore, because of its role in maintaining cellular energy 
homeostasis, PFKFB2 was selected as a plausible PFHBII candidate gene.  
 
ATF3 
Apart from initially being a PFHBII plausible candidate gene by its apparent position within 
the PFHBII locus, ATF3 was chosen for its expression in cardiomyocytes and for its role in 
eliciting hypertrophic response in cardiac tissue of transgenic mice models (Okamoto et al., 
2001). ATF3 encodes an activating transcription factor 3 (ATF3), a member of the CREB/ATF 
family of basic region-leucine zipper transcription factors (Brindle and Montminy, 1992). 
ATF3 mRNA levels are increased in the heart after myocardial ischemia-reperfusion, in the 
kidneys after renal ischemia-reperfusion, in the skin after wounding, in the brain after seizure 
and in the liver after chemical toxicity and partial hepatectomy (Chen et al., 1996; Yin et al., 
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1997). In vitro studies performed with cultured cells also indicated that ATF3 is induced by 
cytokines (Drysdale et al., 1996; Farber, 1992), genotoxic agents and agents that are known to 
induce cell death (Amundson et al., 1999; Liang et al., 1996). The induction of ATF3 by 
myocardial ischemia-reperfusion was also demonstrated in in vivo studies performed with rat 
models, in which the animals were treated with coronary artery ligation coupled with 
reperfusion, to mimic myocardial ischemia-reperfusion (Okamoto et al., 2001). Myocardial 
ischemia-reperfusion in the rat model increased the mRNA levels of ATF3. Okamoto and co-
workers also investigated the effect of elevated ATF3 mRNA levels in transgenic mice models. 
Elevated ATF3 mRNA levels resulted in bi-atrial enlargement and an increase in heart-body 
weight, which was due to cardiac hypertrophy. In addition to hypertrophy, the transgenic mice 
showed atrial and right ventricular dilation. Myocyte disarray, degenerating mitochondria, 
abnormal Z-lines, vacuoles, granules and degenerating intercalated disks were also noted. The 
transgenic mice also demonstrated altered AV node conduction. These studies indicate that 
expression of ATF3 in the heart results in conduction abnormalities and cardiomyopathies, 
suggesting that ATF3 induction by stress signals may play a role in the pathogenesis of stress-
associated cardiac diseases.  
 
Another member of the CREB/ATF family, the cAMP-responsive element-binding protein 
(CREB), has also been implicated in cardiac diseases (Fentzke et al., 1998; Leiden, 1997). 
Transgenic mice expressing a dominant-negative form of CREB have been shown to develop 
four-chambered DCM. These findings indicate that CREB is important for normal functioning 
of the heart, while the studies performed on ATF3 suggest that this gene may play a role in 
cardiac stress responses, as it is not detected in the heart under nonstressed conditions. ATF3 
has also been reported to be a downstream target for the c-Jun N-terminal and p38 stress 
kinases, which are implicated to play a role in promoting cardiac pathology, including myocyte 
hypertrophy and apoptosis (Yue et al., 2000; Turner et al., 1998). 
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Although PFKFB2 and ATF3 were initially chosen as PFHBII plausible candidate genes, they 
were later mapped outside the PFHBII locus due to errors in the order of markers on physical 
maps, which can be caused by problems with assembly of bacterial artificial chromosome 
(BAC) clones. Such problems were noted not only in chromosome 1, but in other 
chromosomes as well (DeWan et al., 2002). For example, in the draft human genome sequence 
released on October 2000, a clone (AC037449.2) derived from chromosome 10 that contains 
several markers (D10S1225, D10S2278, SHGC-130658, stSG29297 and stSG43409) was 
misassembled onto chromosome 14 (DeWan et al., 2002). BAC libraries were used in human 
genome sequencing as a source of substrate for shotgun sequencing project and restriction 
fingerprints for building overlapping clone sets (International Human Genome Sequencing 
Consortium, 2001). BACs also provided information for mapping sequence contigs to 
localised genomic regions by using a direct genomic shotgun sequencing approach. However, 
the disadvantage of using BACs is the occurrence of rearrangement in approximately 10% of 
the clones, which can result in errors in the order of markers (Osoegawa et al., 2001). Further 
problems in assembly can be due to the location of markers near gaps in physical-sequence 
data and to errors in in silico mapping. Filling of gaps in the human genome sequence and 
gene annotation changes have been shown to occur frequently throughout the progress of the 
HGP (DeWan et al., 2002).  
 
4.1.3.2 UCSC gene identification tools 
UCSC gene prediction tools were also used to identify other strong candidate genes harboured 
at the PFHBII locus after the announcement of the completion of the HGP. These genes were 
chosen as plausible PFHBII candidates based on predicted functions of their products. The 
proteins encoded by these active genes are predicted to have functions that include regulation 
of apoptosis, nucleic acid (DNA) binding, ATP-dependent transportation of molecules in the 
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mitochondrion (mitochondrial carrier proteins), plasma membrane calcium transportation, 
transcription regulation, signal transduction, and phospholipid metabolism. The rationale for 
their selection for future mutation screening is discussed below. 
 
Regulation of apoptosis- G0S2 
The putative lymphocyte G0/G1 switch gene (G0S2) is predicted to play a role in regulation of 
apoptosis. Apoptosis is one of the late changes in end-stage heart failure, which include 
changes in gene expression profile, contractile dysfunction and interstitial remodeling in 
response to persisting cardiac stress (Petrich and Wang, 2004). The origin of heart failure 
ranges from hypertension and coronary artery diseases to genetic defects, with cardiac 
hypertrophy developing as a compensatory response that improves the heart’s contractility and 
function (reviewed by Frey and Olson, 2003). The role of apoptosis in heart failure has been 
supported by the upregulation of genes involved in apoptosis (e.g., voltage-dependent anion 
channel 1 and 2, prostaglandin synthase D, and kallikrein 11), which was detected in a gene 
expression profile study performed with sample biopsies of DCM-affected individuals 
(Grzeskowiak et al., 2003).  
 
Mitochondrial carrier proteins- FLJ25078 
The FLJ25078 gene encodes a protein that is functionally related to the Ca2+- and ATP-
binding mitochondrial carrier proteins. Mitochondria carry out various processes that are 
important for cellular development and survival (reviewed by Wallace, 2001). These processes 
include energy generation (citric acid cycle and fatty acid β-oxidation), amino acid synthesis 
and degradation (urea cycle), the synthesis of iron–sulphur clusters and haem, and the 
generation of heat by dissipation of the proton gradient. To achieve this, the mitochondria must 
transport solutes between the mitochondrial matrix and the cytoplasm. Many of the transport 
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steps are carried out over the inner mitochondrial membrane by the mitochondrial carrier 
proteins.  
 
Transcription regulation and signal transduction- RAMP zinc finger protein 198, IRF6 and 
TRAF5 
The interferon receptor factor 6 (IRF6) and RA-regulated nuclear matrix-associated protein 
(RAMP)-zinc finger proteins are predicted to play a role in regulation of transcription 
(Mamane et al., 1999). The tumor necrosis factor receptor-associated 5 (TRAF5) is predicted 
to play a role in signal transduction (Song et al., 1997). Signal transduction and re-induction of 
gene expression have been reported to be among of the changes that occur due to an increase 
in biochemical stress in cardiomyocytes (reviewed by Frey and Olson, 2003). Cardiac 
hypertrophy develops in response to this increase in biochemical stress, which can be caused 
by extrinsic factors such as hypertension or valvular heart disease, or intrinsic factors such as 
gene defects. Cardiac hypertrophy is usually preceded and accompanied by re-induction of 
transcription, the downsteam target of Ca2+-dependent signal transduction pathways that are 
activated through the G protein-coupled receptors (Frey and Olson, 2003). The role of 
transcription factors in cardiac disorders is also supported by the fact that PRKAG2 has been 
implicated as causing HCM that is complicated with conduction defects (section 1.4.3 and 
1.5.2). Molecular characterisation of AMPK revealed the existence of mammalian AMPK 
homology to the yeast SNF-1 and plant SnRK transcription factors, although its gene 
expression regulation in mammals has not been investigated (Carlson, 1999; Halford and 
Hardie, 1998; Alderson et al., 1991). 
 
Phospholipid metabolism- KIAA0205  
The protein encoded by KIAA0205 is predicted to play a functional role in phospholopid 
metabolism. The role of proteins involved in phospholipid metabolism in cardiac function is 
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supported by the fact that energy generation in the heart is dependent on ATP production by 
mitochondrial oxidation of long-chain fatty acids (Randle et al., 1963). In hypertrophic 
cardiomyocytes, fatty acid oxidation is suppressed and glucose utilisation favored. Genes 
involved in fatty acid oxidation are regulated by a family of transcription factors, the 
peroxisome proliferator-activated receptors (PPARs) (Barger and Kelly, 2000). Functional 
studies performed on transgenic mice with a mutant PPAR gene demonstrated embryonic 
lethality due to myocardial defects (Barak et al., 1999). Genes involved in cholesterol 
synthesis (e.g., hydroxymethylglutaryl coenzyme A reductase) have also been implicated in 
hypertrophic signalling (Laufs et al., 2002). These findings suggest that genes and proteins 
involved in lipid metabolism may play a role in cardiac abnormalities. 
 
Gene expression profiling in DCM and HCM 
Gene expression studies performed on cardiac tissue biopsies of DCM- and HCM-affected 
individuals showed changes in expression levels of a variety of genes (Lim et al., 2001, 
Grzeskowiak et al., 2003). Although PFKFB2 and ATF3 were not specifically identified in 
these studies, the classes of genes in which changed expression profiles were reported included 
those encoding contractile sarcomeric and cytoskeletal proteins, ion channels, intracellular 
signal transducers, proteins maintaining the redox state of the myocardium, along with 
transcriptional and translational machinery (Lim et al., 2001, Grzeskowiak et al., 2003).  
 
The expression profile studies provided a resource to investigate if any of the genes identified, 
or those with analogous functions, map to the PFHBII locus and, therefore, are candidate genes 
to screen in future mutation analysis. 
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4.2 Mutation analysis of candidate genes in the PFHBII family 
4.2.1 Search for PFHBII-causing mutations in the PFHBII family 
4.2.1.1 PFKFB2 
PFKFB2 was screened for PFHBII-causing mutations because, at the time of the present study, 
it was localised within the PFHBII locus as indicated in figure 3.1. No PFHBII-causing 
mutation was identified in this gene. The different electrophoretic band patterns identified in 
exon 8 did not represent sequence variants, as there were no nucleotide changes detected in 
sequenced amplicons. The reason for this is unknown since no paper has been published that 
explains the presence of mobility shifts that are not the result of sequence changes in the SSCP 
gels. Possible explanations may be that the extra bands detected were either PCR artefacts, or 
alternative stable conformers of the wild type sequence that were formed due to the exposure 
of samples to subtle variations in salt concentrations (de Lange, Phd thesis). 
 
Mutations have been reported in the promoter regions of several genes that may either increase 
or decrease the expression level of a gene (Papassotiropoulos et al., 2001; Pola et al., 2002; 
Ross et al., 2004). A change in the expression level of a gene may influence the development 
of a particular disease. For example, polymorphisms in the promoter regions of the IL6 and 
TNFα genes were reported to affect gene expression levels, which has been observed in 
individuals with Alzheimer’s disease (Papassotiropoulos et al., 2001; Pola et al., 2002). 
Therefore, a 500bp-PFKFB2 promoter region was also screened for the PFHBII-causing 
mutation but no disease-causing mutation was identified. The reason for analysing only this 
region of the promoter is that five transcription-binding sites (three Sp1- and two HNF1-
binding sites) were identified only in this part of the PFKFB2 promoter through alignment 
with the R. norvegicus pfkfb2 promoter region (Fig 3.4) (Heine-Suner et al., 1998), while none 
has been reported in the remaining 5’ untranslated region of the gene. However, the role of 
these transcription-binding sites in the regulation of PFKFB2 is unknown since their role in 
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promoter activity has not been studied. PFKFB2 was excluded as a plausible candidate for 
PFHBII-causing mutation because it was later mapped outside the PFHBII locus.  
 
4.2.1.2 ATF3 
No PFHBII-causing mutation was identified in the three exons of ATF3 that encode its 
functional domains. The ATF3 promoter region was also analysed for PFHBII-causing 
mutations in the PFHBII family and no PFHBII-causing mutation was identified. ATF3 was 
later localised outside the PFHBII region, and therefore, also excluded as a strong candidate 
gene for PFHBII-causing mutations. 
 
4.3 Mutation analysis of candidate genes in the HCM panel 
4.3.1 Search for HCM main locus and /or HCM-modifying mutations 
Although PFKFB2 and ATF3 were localised outside the PFHBII locus during the later stages 
of the project, they still qualified as plausible candidate genes for HCM causal and/or HCM 
modifying mutations, as HCM genetic modifiers can be located in any chromosomal region. 
 
4.3.1.1 PFKFB2 
Analysis of PFKFB2 for possible HCM main locus and/or modifying mutations revealed a 
11535G/A transition substitution in exon 5 of one HCM-affected individual (Figs 3.9 and 
3.10). However, this variant affected neither an amino acid residue nor a splice junction, and, 
therefore, is most unlikely to have any effect on HCM phenotype. A 500bp-promoter region of 
PFKFB2 was also screened for HCM main locus and/or modifying mutations but no sequence 
variants were identified (Fig. 3.11). However, the remaining part of the promoter region still 
requires mutation analysis to make conclusions regarding the potential role of PFKFB2 in 
modifying the phenotypic expression of HCM.  
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4.3.1.2 ATF3 
The ATF3 coding region was analysed for HCM-causing and/or modifying mutations and no 
sequence variants were identified. The promoter region of the gene was also screened for 
mutations that may cause HCM or modulate its phenotypic expression. Mobility shifts were 
identified in three fragments of the ATF3 promoter region (Figs. 3.13, 3.15, 3.18 and 3.23). 
Automated sequencing of three amplicons with different electrophoretic band patterns revealed 
a sequence variant (-1617A/G transition substitution) and a C nucleotide at position -1688 (not 
a T as detected in the published sequence) in fragment 3 of the ATF3 promoter region (Fig. 
3.14). However, whether the C or T nucleotide was present in other individuals that were 
analysed by PCR-SSCP method is unknown, as only three amplicons were sequenced. No 
additional sequence variant was identified in the third amplicon. Genotyping of affected 
individuals in the HCM panel and their family members revealed two genotypes in fragment 3 
at position -1617: AA homozygotes and AG heterozygotes. The genotypes identified in 
fragment 3 could not be confirmed by ASREA, as these variants did not affect restriction 
enzyme recognition sites.  
 
Three electrophoretic band patterns were detected in fragment 5 of the ATF3 promoter region 
(Fig 3.15). Automated sequencing of the amplicons with different patterns revealed two 
sequence variants (Figs. 3.16 and 3.17). Amplicons of fragment 5 were re-analysed by ASREA 
to confirm the presence of sequence variants and to determine the genotype of other affected 
individuals in the HCM panel and their family members, as genotyping could not be performed 
by PCR-SSCP due to difficulties in interpreting different electrophoretic banding patterns. 
Several genotypes were identified in fragment 5 at positions -1068 and -1229, respectively, 
among the HCM probands and their family members: G/C-C/C, G/C-C/T, G/G-C/C and G/G-
C/T (Figs. 3.24 and 3.25).  
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Two other variants were identified in fragments 6 and 8: -839T/A in fragment 6 (3.19) and -
282A/G in fragment 8 (Fig. 3.23). Genotyping of individuals in the HCM panel and their 
families performed using PCR-SSCP analysis revealed two genotypes at position -839, the TT 
and TA genotypes. The genotypes could not be confirmed by ASREA, as these variants did not 
affect restriction enzyme recognition sites. Although two amplicons showed different 
electrophoretic mobility patterns on an SSCP gel, sequencing revealed that both were -282A/G 
heterozygotes. It was also not possible to confirm the genotypes of other individuals in the 
HCM panel and families using ASREA as the variant did not affect a restriction enzyme 
recognition site. 
 
The data showed that the presence of the ATF3 promoter region -282A/G variant could not be 
consistently detected as a mobility shift on SSCP gels. The sequence variant was only reliable 
detected by automated sequencing. This confirms the findings reported in previous studies that 
the PCR-SSCP analysis can detect approximately 80% of sequence variants (Sheffeld et al., 
1993). Although in the present study, the sensitivity of the method was increased to 
approximately 98% by using different conditions (8% and 10% mild denaturing conditions), it 
has been shown that a small percentage was still not accounted for in experiments using known 
mutations under these conditions (de Lange, PhD thesis).  
 
The sequence variants identified in the ATF3 promoter region were found in both affected and 
unaffected individuals in probands HCM panel and their family members, therefore, they were 
not HCM main locus mutations. Futhermore, the variants did not affect any of the 
transcription-binding sites within the region, although the -1617A/G variant detected in 
fragment 3 is located one nucleotide away from the Myc/Max-binding site, one of the sites 
including E2F, implicated in cell cycle regulation (Liang et al., 1996). It is not clear, however, 
whether the Myc/Max site is functionally important for the ATF3 promoter activity. The ATF3 
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promoter region has been reported to contain various transcription factor-binding sites, 
belonging to two groups: the inducible sites and sites implicated in cell cycle regulation (Liang 
et al., 1996). Inducible sites include ATF/CREB, AP1 and NF-kB sites, which were 
demonstrated to be induced by signals such as cAMP, calcium influx, UV irradiation and 
cytokines (Meyer and Habener, 1993; Roesler et al., 1988).  
 
In the present study, no functional studies were performed to determine the effect of different 
genotypes identified on ATF3 promoter activity and gene expression level. Previous studies 
performed with ATF3 in transgenic mice models demonstrated cardiac abnormalities caused by 
elevated ATF3 mRNA levels (Okamoto et al., 2001). However, QTDT analysis was performed 
in an attempt to determine the association between the identified genotypes and HCM 
quantitative phenotypes that are used in the disease diagnosis.  
 
4.4 QTDT analysis 
QTDT is a family based test that is used to determine linkage between alleles and phenotypes 
and the increased transmission of one allele at a polymorphic locus between affected parent 
and affected children within a family (Abecasis et al., 2000). The test was used in the present 
study as a pilot investigation of the possible association between the genotypes identified in 
the ATF3 promoter region and four HCM-related quantitative traits (LVM, IVS, LVPW and 
LVED) that were measured by echocardiographic analysis as HCM diagnostic criteria (Maron 
et al., 1978). However, statistical analysis could only be performed for one variation, -839T/A, 
as the QTDT program requires sufficient numbers (at least 30) of heterozygous individuals 
before commencing analysis. Only the -839T/A gene variant was sufficiently informative in 
the HCM families to perform the analysis and no significant p-values were obtained as an 
indication of the presence of association between the alleles and HCM traits (table 3.6). 
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Additional clinical data for other traits (e.g., body mass index and blood pressure), that are 
equally important, were not available to pursue the analysis further. 
 
At this stage, it is difficult to draw any conclusions about whether or not ATF3 is a modifier of 
HCM phenotype because of insufficient QTDT data, and the fact that functional studies were 
not performed to determine the effect of the genotypes identified in the promoter region on the 
expression level of the gene.  
 
4.5 Future studies 
The two genes, PFKFB2 and ATF3, were excluded as the PFHBII-causative gene because the 
disease–causative mutation was not identified upon extensive analyses of these genes, in 
addition to the fact that they were later mapped outside the PFHBII locus. Other candidate 
genes still need to be screened for both PFHBII-causing and HCM-causing and/or modifying 
mutations. Mutation screening of these genes and determination of their possible role in 
cardiac tissue will give insight on mechanisms underlying PFHBII and HCM. A molecular 
cause of PFHBII still remains to be identified as no causal mutation was identified in the 
present studies and none has been reported by other investigators yet (Fernandez, PhD thesis 
2004). The genetic causes of HCM are not fully understood as the disease-causative genes 
identified to date only account for approximately 60% of FHC cases (Watkins, 2003). There is 
still a mystery surrounding the genetic factors that may contribute to the development and 
phenotypic expression of HCM. Although several genes have been reported that may play a 
role in modulating the disease phenotype, SNP association studies performed with these genes 
have given conflicting data that which may be due to linkage among polymorphisms within 
several genes.  
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Identification of the PFHBII-causative gene will allow a DNA-based diagnosis that will 
surpass the current use of genetic markers, which is limited to a family setting. It will also 
help in elucidation of the underlying molecular mechanisms that cause PFHBII. Furthermore, 
identification of both HCM-modifying and HCM-causing genes will give insight into the 
phenotypic variability noted among South African HCM-affected individuals and into the 
molecular cause of the disease among individuals with HCM-like clinical features. This may 
lead to the development of more directed therapies that may have application to both familial 
and sporadic forms of cardiac abnormalities in the general population. 
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APPENDIX I 
URLS OF THE WEBSITES USED IN THE STUDY 
http://www.cotc.edu/vstone/webdocek.html 
http://www.cotc.edu/vstone/webdocek.html 
http://www.embl.de/~wendt/ troponin.html 
http://www.ensembl.org/Homo_sapiens/stats/status.html 
http://www.ncbi.nlm.nih.gov 
http://www.ncbi.nlm.nih.gov/BLAST 
http://www.ensembl.org/ 
http://www.ensembl.org/Multi/blastview?species=Homo_sapiens 
http://www.hopkinsmedicine.org/cardiology/ heart/photographs.html 
http://cardiogenomics.med.harvard.edu/project-detail?project_id=230 
http://www.sph.umich.edu/csg/abecasis/QTDT/ 
http://www.ebi.ac.uk/emboss/align/index.html 
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APPENDIX II 
BUFFERS, MARKERS AND SOLUTIONS 
 
1 BUFFERS 
 
1.1. CELL LYSIS BUFFER 
Sucrose  0.32M 
Triton-X-100  1% 
MgCl2   5mM 
Tris-HCl  10mM 
H2O  1l 
 
1.2. DNA EXTRACTION BUFFER 
NaCl   0.1M 
Tris-HCl  0.01M 
EDTA (pH8)  0.025M 
SDS   0.5% 
Proteinase K  0.1mg/ml 
 
1.3. TBE-BUFFER (10x stock) 
Tris-HCl  0.89M 
Boric Acid  0.89M 
Na2EDTA (pH8) 20mM 
 
1.4. TE-BUFFER (10x stock) 
TrisOH  0.1M 
EDTA(pH8)  0.01M 
H2O   150ml 
 
1.5. Taq POLYMERASE BUFFER (Bioline) 
Ammonium sulphate   160mM 
Tris-HCl (pH 8.8)   670mM 
Tween-20    0.1% 
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2. SOLUTIONS 
 
2.1. SOLUTIONS FOR POLYACRYLAMIDE GELS 
2.1.1. Acrylamide-Bis (ready-to-use) solution 40% (37:5:1) 
2.1.2. 10% AMMONIUMPERSULPHATE (APS) 
APS      2g 
H2O      20ml 
 
2.2. SOLUTIONS FOR SILVER STAINING 
2.2.1. 0.1% AgNO3 (Solution B) 
AgNO3      1g 
H2O      1L 
 
2.2.2. DEVELOPING SOLUTION (Solution C) 
NaOH      15g 
NaBH4      0.1g 
Formaldehyde     4ml 
H2O      1L 
 
3. GELS 
3.1. 12% POLYACRYLAMIDE GEL 
40% Acrylamide-Bis (ready-to-use) solution  3ml 
10xTBE      1ml 
Distilled H2O      6ml 
APS       80μl 
TEMED      30μl 
 
3.2. 10% MILDLY DENATURING POLYACRYLAMIDE GEL WITH 5% 
GLYCEROL 
40% Acrylamide-Bis (ready-to-use) solution  40.5ml 
10xTBE      8ml 
Glycerol      8ml 
Urea       24g 
Distilled H2O      84ml 
APS       1600μl 
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TEMED      160μl 
 
3.3. 8% MILDLY DENATURING POLYACRYLAMIDE GEL WITH 5% 
GLYCEROL 
40% Acrylamide-Bis (ready-to-use) solution    32.4ml 
10xTBE        8ml 
Glycerol        8ml 
Urea         24g 
Distilled H2O        91.8ml 
APS         1600μl 
TEMED        160μl 
 
4. LOADING DYES 
4.1. BROMOPHENOL BLUE 
Bromophenol blue 0.2%(w/v) 
Glycerol  50% 
Tris (pH8)  10mM 
 
4.2. SSCP LOADING DYE 
Formamide  95% 
EDTA   20mM 
Bromophenol blue 0.01% 
Xylene cyanol  0.05g 
NaOH   10mM 
 
5. MOLECULAR WEIGHT MARKER (LAMBDA PstI) 
Bacteriophage Lambda DNA (250μg)  100μl 
Buffer M (Boerhinger Mannhein)   15μl 
PstI (Boerhinger Mannheim)    11μl 
H2O       32μl 
Incubate at 37°C for 2 hours followed by heat inactivation at 65°C for 5 minutes. Load 2μl 
onto polyacrylamide gels. 
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APPENDIX III 
LIST OF SUPPLIERS 
 
Acrylamide-Bis (ready-to-use) solution    Promega 
AgNO3       Merck 
Alw 26I       Sigma 
Ammonium persulphate     Merck 
Boric acid       Merck 
Bromophenol blue      Merck 
dGTP        Boerhinger Mannheim 
dCTP        Boerhinger Mannheim 
dTTP        Boerhinger Mannheim 
dATP        Boerhinger Mannheim 
EcoRV        Promega 
EDTA        Boerhinger Mannheim 
Ethanol       Boerhinger Mannheim 
Formamide       Merck 
Formaldeyde       Merck 
Gelbond       Merck 
GFXTM PCR DNA and Gel Band Purification Kit  Amersham Bioscience 
Glycerol       FMC 
K-acetate       Sigma 
KCl        Merck 
Lambda DNA       Promega 
Mineral oil       BDH Chemicals 
NaAc        Merck 
NaCl        BDH Chemicals 
NaOH        Sigma 
NlaIII        New England Biolabs 
Phenol        Merck 
PBS        Sigma 
SDS        Sigma 
Taq polymerase      Bioline 
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TEMED       Sigma 
Tris        Merck 
Tris-OH       Merck 
Tris-HCl       Merck 
Urea        BDH Chemicals 
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